










































THE CONCISE GUIDE TO PHARMACOLOGY 2017/18
Citation for published version:
Alexander, SP, Striessnig, J, Kelly, E, Marrion, NV, Peters, JA, Faccenda, E, Harding, SD, Pawson, AJ,
Sharman, JL, Southan, C, Davies, JA & CGTP Collaborators 2017, 'THE CONCISE GUIDE TO
PHARMACOLOGY 2017/18: Voltage-gated ion channels' British Journal of Pharmacology, vol. 174 Suppl 1,
pp. S160-S194. DOI: 10.1111/bph.13884
Digital Object Identifier (DOI):
10.1111/bph.13884
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
British Journal of Pharmacology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Voltage-gated
ion
channels.British
JournalofPharm
acology
(2017)174,S160–S194
TH
E
C
O
N
C
ISE
G
U
ID
E
TO
PH
A
RM
A
C
O
LO
G
Y
2017/18:
Voltage-gated
ion
channels
Steph
en
PH
A
lexan
der 1,Jörg
Striessn
ig
2,Eam
on
n
K
elly
3,N
eilV
M
arrion
3,Joh
n
A
Peters 4,Elen
a
Faccen
da
5,
Sim
on
D
H
ardin
g
5,A
dam
J
Paw
son
5,Joan
n
a
L
Sh
arm
an
5,C
h
ristoph
er
South
an
5,
Jam
ie
A
D
avies 5
an
d
C
G
TP
C
ollaborators
1
SchoolofLife
Sciences,U
niversity
ofN
ottingham
M
edicalSchool,N
ottingham
,N
G
7
2U
H
,U
K
2
Pharm
acology
and
Toxicology,Institute
ofPharm
acy,U
niversity
ofInnsbruck,A
-6020
Innsbruck,A
ustria,
3
SchoolofPhysiology,Pharm
acology
and
N
euroscience,U
niversity
ofBristol,Bristol,BS8
1T
D
,U
K
4
N
euroscience
D
ivision,M
edicalEducation
Institute,N
inew
ells
H
ospitaland
M
edicalSchool,U
niversity
ofD
undee,D
undee,D
D
1
9SY,U
K
5
C
entre
for
Integrative
Physiology,U
niversity
ofEdinburgh,Edinburgh,EH
8
9X
D
,U
K
A
b
stract
Th
e
C
on
cise
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
2017/18
provides
con
cise
overview
s
of
th
e
key
properties
of
n
early
1800
h
um
an
drug
targets
w
ith
an
em
ph
asis
on
selective
ph
arm
acology
(w
h
ere
available),
plus
lin
ks
to
an
open
access
kn
ow
ledgebase
of
drug
targets
an
d
th
eir
ligan
ds
(w
w
w
.guidetoph
arm
acology.org),w
h
ich
provides
m
ore
detailed
view
s
of
target
an
d
ligan
d
properties.
A
lth
ough
th
e
C
on
cise
G
uide
represen
ts
approxim
ately
400
pages,th
e
m
aterial
presen
ted
is
substan
tially
reduced
com
pared
to
in
form
ation
an
d
lin
ks
presen
ted
on
th
e
w
ebsite.
It
provides
a
perm
an
en
t,citable,poin
t-in
-tim
e
record
th
at
w
ill
survive
database
updates.
Th
e
full
con
ten
ts
of
th
is
section
can
be
foun
d
at
h
ttp://on
lin
elibrary.w
iley.com
/doi/10.1111/bph
.13884/full.
V
oltage-gated
ion
ch
an
n
els
are
on
e
of
th
e
eigh
t
m
ajor
ph
arm
acologicaltargets
in
to
w
h
ich
th
e
G
uide
is
divided,w
ith
th
e
oth
ers
bein
g:
G
protein
-coupled
receptors,ligan
d-gated
ion
ch
an
n
els,oth
er
ion
ch
an
n
els,n
uclear
h
orm
on
e
receptors,catalytic
receptors,en
zym
es
an
d
tran
sporters.Th
ese
are
presen
ted
w
ith
n
om
en
clature
guidan
ce
an
d
sum
m
ary
in
form
ation
on
th
e
best
available
ph
arm
acologicaltools,alon
gside
key
referen
ces
an
d
suggestion
s
for
furth
er
readin
g.Th
e
lan
dscape
form
at
ofth
e
C
on
cise
G
uide
is
design
ed
to
facilitate
com
parison
ofrelated
targets
from
m
aterialcon
tem
porary
to
m
id-2017,an
d
supersedes
data
presen
ted
in
th
e
2015/16
an
d
2013/14
C
on
cise
G
uides
an
d
previous
G
uides
to
R
eceptors
an
d
C
h
an
n
els.
It
is
produced
in
close
con
jun
ction
w
ith
th
e
N
om
en
clature
C
om
m
ittee
of
th
e
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology
(N
C
-IU
PH
A
R
),th
erefore,providin
g
officialIU
PH
A
R
classification
an
d
n
om
en
clature
for
h
um
an
drug
targets,w
h
ere
appropriate.
C
o
n
fl
ict
o
f
in
terest
Th
e
auth
ors
state
th
at
th
ere
are
n
o
con
flicts
of
in
terest
to
declare.
©
2017
Th
e
A
uth
ors.British
Journ
alof
Ph
arm
acology
publish
ed
by
Joh
n
W
iley
&
Son
s
Ltd
on
beh
alf
of
British
Ph
arm
acologicalSociety.
Th
is
is
an
open
access
article
un
der
th
e
term
s
ofth
e
C
reative
C
om
m
on
s
A
ttribution
Licen
se,w
h
ich
perm
its
use,distribution
an
d
reproduction
in
an
y
m
edium
,provided
th
e
origin
alw
ork
is
properly
cited.
Fam
ily
stru
ctu
re
S161
C
atSper
an
d
Tw
o-Pore
ch
an
n
els
S162
C
yclic
n
ucleotide-regulated
ch
an
n
els
S164
Potassium
ch
an
n
els
S165
C
alcium
-an
d
sodium
-activated
potassium
ch
an
n
els
S166
In
w
ardly
rectifyin
g
potassium
ch
an
n
els
S169
Tw
o
P
dom
ain
potassium
ch
an
n
els
S171
V
oltage-gated
potassium
ch
an
n
els
S175
R
yan
odin
e
receptors
S176
Tran
sien
t
R
eceptor
Poten
tialch
an
n
els
S186
V
oltage-gated
calcium
ch
an
n
els
S188
V
oltage-gated
proton
ch
an
n
el
S189
V
oltage-gated
sodium
ch
an
n
els
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C
atSper
and
Tw
o-Pore
channels
V
oltage-gated
ion
ch
an
n
els→
C
atSper
an
d
Tw
o-Pore
ch
an
n
els
O
verview
:
C
atSper
ch
an
n
els
(C
atSper1-4,
n
o
m
en
clatu
re
as
ag
reed
b
y
N
C
-IU
P
H
A
R
[69])
are
putative
6TM
,
voltage-gated,
calcium
perm
ean
t
ch
an
n
els
th
at
are
presum
ed
to
assem
ble
as
a
tetram
er
ofα
-like
subun
its
an
d
m
ediate
th
e
curren
t
IC
atSper
[193].
In
m
am
m
als,C
atSpersubun
itsare
structurally
m
ostclosely
related
to
in
dividualdom
ain
sofvoltage-activated
calcium
ch
an
n
els(C
av )
[349].
C
atSper1
[349],C
atSper2
[341]
an
d
C
atSpers
3
an
d
4
[173,
245,338],in
com
m
on
w
ith
a
putative
2TM
auxiliary
C
atSperβ
pro-
tein
[242]an
d
tw
o
putative
1TM
associated
C
atSperγ
an
d
C
atSperδ
protein
s
[64,434],are
restricted
to
th
e
testis
an
d
localised
to
th
e
prin
ciple
piece
of
sperm
tail.
Tw
o-pore
ch
an
n
els
(TPC
s)
are
structurally
related
to
C
atSpers,
C
aV
san
d
N
aV
s.TPC
sh
ave
a
2x6TM
structure
w
ith
tw
ice
th
e
n
um
-
ber
of
TM
s
of
C
atSpers
an
d
h
alf
th
at
of
C
aV
s.
Th
ere
are
th
ree
an
-
im
al
TPC
s
(TPC
1-TPC
3).
H
um
an
s
h
ave
TPC
1
an
d
TPC
2,
but
n
ot
TPC
3.
TPC
1
an
d
TPC
2
are
localized
in
en
dosom
es
an
d
lysosom
es
[43].
TPC
3
is
also
foun
d
on
th
e
plasm
a
m
em
bran
e
an
d
form
s
a
voltage-activated,
n
on
-in
activatin
g
N
a +
ch
an
n
el
[44].
A
ll
th
e
th
ree
TPC
s
are
N
a +-selective
un
der
w
h
ole-cellor
w
h
ole-organ
elle
patch
clam
p
recordin
g
[45,
46,
457].
Th
e
ch
an
n
els
m
ay
also
con
duct
C
a 2+
[272].
N
om
enclature
C
atSper1
C
atSper2
C
atSper3
C
atSper4
H
G
N
C
,U
niProt
CATSPER1,Q
8N
EC
5
CATSPER2,Q
96P56
CATSPER3,Q
86X
Q
3
CATSPER4,Q
7RTX
7
Activators
C
atSper1
is
constitutively
active,w
eakly
facilitated
by
m
em
brane
depolarisation,strongly
augm
ented
by
intracellular
alkalinisation.In
hum
an,but
not
m
ouse,sperm
atozoa
progesterone
(EC
50 ˜8
nM
)
also
potentiates
the
C
atSper
current
(IC
atSper )
[239,390]
–
–
–
C
hannelblockers
ruthenium
red
(pIC
50
5)
[193]–
M
ouse,H
C
-056456
(pIC
50
4.7)
[50],
C
d
2+
(pIC
50
3.7)
[193]–
M
ouse,N
i 2+
(pIC
50
3.5)
[193]–
M
ouse
–
–
–
Selective
channelblockers
N
N
C
55-0396
(pIC
50
5.7)
[-80m
V
–
80m
V][239,390],m
ibefradil
(pIC
50
4.4–4.5)
[390]
–
–
–
FunctionalC
haracteristics
C
alcium
selective
ion
channel(Ba 2+>
C
a 2+≫
M
g
2+≫
N
a +);
quasilinear
m
onovalent
cation
current
in
the
absence
ofextracellular
divalent
cations;
alkalinization
shifts
the
voltage-dependence
ofactivation
tow
ards
negative
potentials
[V
½
@
pH
6.0
=
+87
m
V
(m
ouse);V
½
@
pH
7.5
=
+11m
V
(m
ouse)
or
pH
7.4
=
+85
m
V
(hum
an)];required
for
IC
atSper
and
m
ale
fertility
(m
ouse
and
hum
an)
Required
for
IC
atSper
and
m
ale
fertility
(m
ouse
and
hum
an)
Required
for
IC
atSper
and
m
ale
fertility
(m
ouse)
Required
for
IC
atSper
and
m
ale
fertility
(m
ouse)
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w
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C
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S161
FullC
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N
om
enclature
TPC
1
TPC
2
H
G
N
C
,U
niProt
TPCN
1,Q
9U
LQ
1
TPCN
2,Q
8N
H
X
9
Activators
phosphatidyl(3,5)
inositolbisphosphate
(pEC
50
6.5)
[45]
phosphatidyl(3,5)
inositolbisphosphate
(pEC
50
6.4)
[439]
C
hannelblockers
verapam
il(pIC
50
4.6)
[45],C
d
2+
(pIC
50
3.7)
[45]
verapam
il(pIC
50
5)
[439]
FunctionalC
haracteristics
O
rganelle
voltage-gated
N
a +-selective
channel(N
a +≫
K
+≫
C
a 2+);Required
for
the
generation
ofaction
potential-like
long
depolarization
in
lysosom
es.Voltage-dependence
ofactivation
is
sensitive
to
lum
inalpH
(determ
ined
from
lysosom
alrecordings).
ψ
1/2
@
pH
4.6
=
+91
m
V;ψ
1/2
@
pH
6.5
=
+2.6
m
V.M
axim
um
activity
requires
PI(3,5)P2
and
reduced
[ATP]
O
rganelle
voltage-independent
N
a +-selective
channel
(N
a +≫
K
+≫
C
a 2+).Sensitive
to
the
levels
ofPI(3,5)P2.Activated
by
decreases
in
[ATP]or
depletion
ofextracellular
am
ino
acids
C
o
m
m
en
ts:
C
atSper
ch
an
n
el
subun
its
expressed
sin
gly,
or
in
com
bin
ation
,fail
to
fun
ction
ally
express
in
h
eterologous
expres-
sion
system
s
[341,
349].
Th
e
properties
of
C
atSper1
tabulated
above
are
derived
from
w
h
ole
cellvoltage-clam
p
recordin
gs
com
-
parin
g
curren
ts
en
dogen
ous
to
sperm
atozoa
isolated
from
th
e
corpus
epididym
is
of
w
ild-type
an
dC
atsper1
(-/-)
m
ice
[193]an
d
also
m
ature
h
um
an
sperm
[239,
390].
IC
atSper
is
also
un
detectable
in
th
e
sperm
atozoa
of
C
atsper2
(-/-),C
atsper3
(-/-),
C
atsper4
(-/-),
or
C
atSperδ
(-/-)m
ice,an
d
C
atSper1
associatesw
ith
C
atSper2,3,4,β,
γ,an
d
δ
[64,242,338].M
oreover,targeted
disruption
of
C
atsper1,
2,
3,
4,
or
δ
gen
es
results
in
an
iden
tical
ph
en
otype
in
w
h
ich
sperm
atozoa
fail
to
exh
ibit
th
e
h
yperactive
m
ovem
en
t
(w
h
ip-
like
flagellar
beats)
n
ecessary
for
pen
etration
of
th
e
egg
cum
ulus
an
d
zona
pellucida
an
d
subsequen
t
fertilization
.
Such
disruption
s
are
associated
w
ith
a
deficit
in
alkalin
ization
an
d
depolarization
-
evoked
C
a 2+
en
try
in
to
sperm
atozoa
[51,
64,
338].
Th
us,
it
is
likely
th
at
th
e
C
atSper
pore
is
form
ed
by
a
h
eterotetram
er
of
C
atSpers1-4
[338]
in
association
w
ith
th
e
auxiliary
subun
its
(β,
γ,
δ)
th
at
are
also
essen
tial
for
fun
ction
[64].
C
atSper
ch
an
n
els
are
required
for
th
e
in
crease
in
in
tracellular
C
a 2+
con
cen
tration
in
sperm
evoked
by
egg
zona
pellucida
glycoprotein
s
[457].M
ouse
an
d
h
um
an
sperm
sw
im
again
st
th
e
fluid
flow
an
d
C
a 2+
sign
al-
in
g
th
rough
C
atSper
is
required
for
th
e
rh
eotaxis
[268].
In
vivo,
C
atSper1-n
ull
sperm
atozoa
can
n
ot
ascen
d
th
e
fem
ale
reproduc-
tive
tracts
efficien
tly
[65,
151].
It
h
as
been
sh
ow
n
th
at
C
atSper
ch
an
n
els
form
four
lin
ear
C
a 2+
sign
alin
g
dom
ain
s
alon
g
th
e
flagella,w
h
ich
orch
estrate
capacitation
-associated
tyrosin
e
ph
os-
ph
orylation
[65].Th
e
drivin
g
force
for
C
a 2+
en
try
is
prin
cipally
determ
in
ed
by
a
m
ildly
outw
ardly
rectifyin
g
K
+
ch
an
n
el
(K
Sper)
th
at,
like
C
atSpers,
is
activated
by
in
tracellular
alkalin
ization
[283].
M
ouse
K
Sper
is
en
coded
by
m
Slo3,a
protein
detected
on
ly
in
testis
[262,
283,
478].
In
h
um
an
sperm
,
such
alkalin
ization
m
ay
result
from
th
e
activation
of
H
v 1,
a
proton
ch
an
n
el
[240].
M
utation
s
in
C
atSpers
are
associated
w
ith
syn
drom
ic
an
d
n
on
-
syn
drom
ic
m
ale
in
fertility
[144].
In
h
um
an
ejaculated
sperm
ato-
zoa,
progesteron
e
(<
50
n
M
)
poten
tiates
th
e
C
atSper
curren
t
by
a
n
on
-gen
om
ic
m
ech
an
ism
an
d
acts
syn
ergistically
w
ith
in
tracel-
lular
alkalin
isation
[239,390].
Sperm
cells
from
in
fertile
patien
ts
w
ith
a
deletion
in
C
atSper2
gen
e
lack
IC
atSper an
d
th
e
progesteron
e
respon
se
[375].
In
addition
,
certain
prostaglan
din
s
(e.g.
PG
F1α
,
PG
E
1 )
also
poten
tiate
C
atSper
m
ediated
curren
ts
[239,390].
In
h
um
an
sperm
,
C
atSper
ch
an
n
els
are
also
activated
by
various
sm
allm
olecules
in
cludin
g
en
docrin
e
disruptin
g
ch
em
icals
(ED
C
)
an
d
proposed
as
a
polym
odalsen
sor
[39,39].
TPC
s
are
th
e
m
ajor
N
a +
con
ductan
ce
in
lysosom
es;kn
ockin
g
out
TPC
1
an
d
TPC
2
elim
in
ates
th
e
N
a +
con
ductan
ce
an
d
ren
ders
th
e
organ
elle’s
m
em
bran
e
poten
tial
in
sen
sitive
to
ch
an
ges
in
[N
a +]
(31).
Th
e
ch
an
n
els
are
regulated
by
lum
in
al
pH
[45],
PI(3,5)P2
[439],
in
tracellular
A
TP
an
d
extracellular
am
in
o
acids
[46].
TPC
s
are
also
in
volved
in
th
e
N
A
A
D
P-activated
C
a 2+
release
from
lyso-
som
alC
a 2+
stores
[43,272].M
ice
lackin
g
TPC
s
are
viable
buth
ave
ph
en
otypes
in
cludin
g
com
prom
ised
lysosom
al
pH
stability,
re-
duced
ph
ysicalen
duran
ce
[46],resistan
ce
to
Ebola
viralin
fection
[358]
an
d
fatty
liver
[124].
N
o
m
ajor
h
um
an
disease-associated
TPC
m
utation
h
as
been
reported.
Fu
rth
er
read
in
g
o
n
C
atSp
er
an
d
T
w
o
-P
o
re
ch
an
n
els
C
laph
am
D
E
et
al.
(2005)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
L.
N
om
en
clature
an
d
structure-
fun
ction
relation
sh
ips
of
C
atSper
an
d
tw
o-pore
ch
an
n
els.
Pharm
acol.
Rev.
57
:
451-4
[PM
ID
:16382101]
G
rim
m
C
et
al.
(2017)
Tw
o-Pore
C
h
an
n
els:
C
atalyzers
of
En
dolysosom
al
Tran
sport
an
d
Fun
ction
.
FrontPharm
acol8
:45
[PM
ID
:28223936]
K
in
tzer
A
F
et
al.
(2017)
O
n
th
e
Structure
an
d
M
ech
an
ism
of
Tw
o-Pore
C
h
an
n
els.
FEBS
J
[PM
ID
:28656706]
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C
yclic
nucleotide-regulated
channels
V
oltage-gated
ion
ch
an
n
els→
C
yclic
n
ucleotide-regulated
ch
an
n
els
O
verview
:
C
yclic
n
ucleotide-gated
(C
N
G
)
ch
an
n
els
are
respon
-
sible
for
sign
allin
g
in
th
e
prim
ary
sen
sory
cells
of
th
e
vertebrate
visual
an
d
olfactory
system
s.
A
stan
d
ard
ised
n
o
m
en
clatu
re
fo
r
C
N
G
ch
an
n
els
h
as
b
een
p
ro
p
o
sed
b
y
th
e
N
C
-IU
P
H
A
R
su
b
co
m
m
ittee
o
n
vo
ltag
e-g
ated
io
n
ch
an
n
els
[154].
C
N
G
ch
an
n
elsare
voltage-in
depen
den
tcation
ch
an
n
elsform
ed
as
tetram
ers.
Each
subun
it
h
as
6TM
,w
ith
th
e
pore-form
in
g
dom
ain
betw
een
TM
5
an
d
TM
6.
C
N
G
ch
an
n
els
w
ere
first
foun
d
in
rod
ph
otoreceptors
[107,188],w
h
ere
ligh
t
sign
als
th
rough
rh
odopsin
an
d
tran
sducin
to
stim
ulate
ph
osph
odiesterase
an
d
reduce
in
tra-
cellular
cyclic
G
M
P
level.
Th
is
results
in
a
closure
of
C
N
G
ch
an
-
n
els
an
d
a
reduced
‘dark
curren
t’.Sim
ilar
ch
an
n
els
w
ere
foun
d
in
th
e
cilia
ofolfactory
n
euron
s
[282]an
d
th
e
pin
ealglan
d
[95].Th
e
cyclic
n
ucleotides
bin
d
to
a
dom
ain
in
th
e
C
term
in
us
ofth
e
sub-
un
it
protein
:
oth
er
ch
an
n
els
directly
bin
din
g
cyclic
n
ucleotides
in
clude
H
C
N
,eag
an
d
certain
plan
t
potassium
ch
an
n
els.
N
om
enclature
C
N
G
A1
C
N
G
A2
C
N
G
A3
C
N
G
B3
H
G
N
C
,U
niProt
CN
G
A1,P29973
CN
G
A2,Q
16280
CN
G
A3,Q
16281
CN
G
B3,Q
9N
Q
W
8
Activators
cyclic
G
M
P
(EC
50 ˜30
µ
M
)≫
cyclic
AM
P
cyclic
G
M
P
>
cyclic
AM
P
(EC
50 ˜1
µ
M
)
cyclic
G
M
P
(EC
50 ˜30
µ
M
)≫
cyclic
AM
P
–
Inhibitors
–
–
L-(cis)-diltiazem
(high
affinity
binding
requires
presence
ofC
N
G
B
subunits)
–
C
hannelblockers
dequalinium
(pIC
50
6.7)
[0m
V][355],L-(cis)-diltiazem
(high
affinity
binding
requires
presence
ofC
N
G
B
subunits)
(pK
i 4)
[-80m
V
–
80m
V][58]
dequalinium
(pIC
50
5.6)
[0m
V][354]
–
L-(cis)-diltiazem
(C
hannelblocker
w
hen
C
N
G
B3
coexpressed
w
ith
C
N
G
A3)
(pIC
50
5.5)
[0m
V][116]–
M
ouse
FunctionalC
haracteristics
γ
=
25-30
pS
PC
a /PN
a
=
3.1
γ
=
35
pS
PC
a /PN
a
=
6.8
γ
=
40
pS
PC
a /PN
a
=
10.9
–
C
o
m
m
en
ts:
C
N
G
A
1,C
N
G
A
2
an
d
C
N
G
A
3
express
fun
ction
alch
an
n
els
as
h
om
om
ers.
Th
ree
addition
alsubun
its
C
N
G
A
4
(Q
8IV
77),C
N
G
B1
(Q
14028)
an
d
C
N
G
B3
(Q
9N
Q
W
8)
do
n
ot,an
d
are
referred
to
as
auxiliary
subun
its.Th
e
subun
it
com
position
ofth
e
n
ative
ch
an
n
els
is
believed
to
be
as
follow
s.R
od:C
N
G
A
1
3 /C
N
G
B1a;C
on
e:C
N
G
A
3
2 /C
N
G
B3
2 ;O
lfactory
n
euron
s:C
N
G
A
2
2 /C
N
G
A
4/C
N
G
B1b
[323,
445,480,481,483].
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H
yp
erp
o
larisatio
n
-activated
,
cyclic
n
u
cleo
tid
e-g
ated
(H
C
N
)
ch
an
n
els
Th
e
h
yperpolarisation
-activated,
cyclic
n
ucleotide-gated
(H
C
N
)
ch
an
n
els
are
cation
ch
an
n
els
th
at
are
activated
by
h
yperpolar-
isation
at
voltages
n
egative
to
˜-50
m
V.
Th
e
cyclic
n
ucleotides
cyclic
A
M
P
an
d
cyclic
G
M
P
directly
activate
th
e
ch
an
n
els
an
d
sh
iftth
e
activation
curves
ofH
C
N
ch
an
n
els
to
m
ore
positive
volt-
ages,th
ereby
en
h
an
cin
g
ch
an
n
elactivity.H
C
N
ch
an
n
els
un
derlie
pacem
aker
curren
ts
foun
d
in
m
an
y
excitable
cells
in
cludin
g
car-
diac
cells
an
d
n
euron
s
[92,
308].
In
n
ative
cells,
th
ese
curren
ts
h
ave
a
variety
ofn
am
es,such
as
Ih ,Iq
an
dIf .Th
e
fourkn
ow
n
H
C
N
ch
an
n
els
h
ave
six
tran
sm
em
bran
e
dom
ain
s
an
d
form
tetram
ers.
It
is
believed
th
at
th
e
ch
an
n
els
can
form
h
eterom
ers
w
ith
each
oth
er,as
h
as
been
sh
ow
n
for
H
C
N
1
an
d
H
C
N
4
[7].
A
stan
d
ard
-
ised
n
o
m
en
clatu
re
fo
r
H
C
N
ch
an
n
els
h
as
b
een
p
ro
p
o
sed
b
y
th
e
N
C
-IU
P
H
A
R
su
b
co
m
m
ittee
o
n
vo
ltag
e-g
ated
io
n
ch
an
n
els
[154].
N
om
enclature
H
C
N
1
H
C
N
2
H
C
N
3
H
C
N
4
H
G
N
C
,U
niProt
H
CN
1,O
60741
H
CN
2,Q
9U
L51
H
CN
3,Q
9P1Z3
H
CN
4,Q
9Y3Q
4
Activators
cyclic
AM
P
>
cyclic
G
M
P
(both
w
eak)
cyclic
AM
P
>
cyclic
G
M
P
–
cyclic
AM
P
>
cyclic
G
M
P
C
hannelblockers
ivabradine
(pIC
50
5.7)
[384],ZD
7288
(pIC
50
4.7)
[383],C
s +
(pIC
50
3.7)
[-40m
V]
[383]
ivabradine
(pIC
50
5.6)
[384]–
M
ouse,
ZD
7288
(pIC
50
4.4)
[383],C
s +
(pIC
50
3.7)
[-40m
V][383]
ivabradine
(pIC
50
5.7)
[384],ZD
7288
(pIC
50
4.5)
[383],C
s +
(pIC
50
3.8)
[-40m
V]
[383]
ivabradine
(pIC
50
5.7)
[384],ZD
7288
(pIC
50
4.7)
[383],C
s +
(pIC
50
3.8)
[-40m
V][383]
C
o
m
m
en
ts:
H
C
N
ch
an
n
els
are
perm
eable
to
both
N
a +
an
d
K
+
ion
s,w
ith
a
N
a +/K
+
perm
eability
ratio
of
about
0.2.Fun
ction
ally,th
ey
differ
from
each
oth
er
in
term
s
of
tim
e
con
stan
t
of
activation
w
ith
H
C
N
1
th
e
fastest,H
C
N
4
th
e
slow
est
an
d
H
C
N
2
an
d
H
C
N
3
in
term
ediate.
Th
e
com
poun
ds
ZD
7288
[37]
an
d
ivabradin
e
[42]
h
ave
proven
usefulin
iden
tifyin
g
an
d
studyin
g
fun
ction
al
H
C
N
ch
an
n
els
in
n
ative
cells.Zatebradin
e
an
d
cilobradin
e
are
also
usefulblockin
g
agen
ts.
Fu
rth
er
read
in
g
o
n
C
yclic
n
u
cleo
tid
e-reg
u
lated
ch
an
n
els
H
errm
an
n
S
et
al.
(2015)
H
C
N
ch
an
n
els–m
odulators
of
cardiac
an
d
n
euron
alexcitability.
Int
J
M
ol
Sci16
:1429-47
[PM
ID
:25580535]
H
ofm
an
n
F
et
al.
(2005)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
LI.
N
om
en
clature
an
d
structure-
fun
ction
relation
sh
ips
of
cyclic
n
ucleotide-regulated
ch
an
n
els.
Pharm
acol
Rev
57
:
455-62
[PM
ID
:16382102]
Podda
M
V
et
al.
(2014)
N
ew
perspectives
in
cyclic
n
ucleotide-m
ediated
fun
ction
s
in
th
e
C
N
S:
th
e
em
ergin
g
role
of
cyclic
n
ucleotide-gated
(C
N
G
)
ch
an
n
els.
Pfl
ugers
A
rch
466
:
1241-57
[PM
ID
:24142069]
Tsan
toulas
C
et
al.
(2016)
H
C
N
2
ion
ch
an
n
els:
basic
scien
ce
open
s
up
possibilities
for
th
erapeutic
in
terven
tion
in
n
europath
ic
pain
.Biochem
J473
:2717-36
[PM
ID
:27621481]
Potassium
channels
V
oltage-gated
ion
ch
an
n
els→
Potassium
ch
an
n
els
O
verview
:
A
ctivation
of
potassium
ch
an
n
els
regulates
excitabil-
ity
an
d
can
con
trol
th
e
sh
ape
of
th
e
action
poten
tial
w
aveform
.
Th
ey
are
presen
tin
allcellsw
ith
in
th
e
body
an
d
can
in
fluen
ce
pro-
cesses
as
diverse
as
cogn
ition
,
m
uscle
con
traction
an
d
h
orm
on
e
secretion
.Potassium
ch
an
n
els
are
subdivided
in
to
fam
ilies,based
on
th
eir
structural
an
d
fun
ction
al
properties.
Th
e
largest
fam
-
ily
con
sists
of
potassium
ch
an
n
els
th
at
activated
by
m
em
bran
e
depolarization
,
w
ith
oth
er
fam
ilies
con
sistin
g
of
ch
an
n
els
th
at
are
eith
er
activated
by
a
rise
of
in
tracellular
calcium
ion
s
or
are
con
stitutively
active.
A
stan
dardised
n
om
en
clature
for
potassium
ch
an
n
els
h
as
been
proposed
by
th
e
N
C
-IU
P
H
A
R
su
b
co
m
m
it-
tees
on
potassium
ch
an
n
els
[120,
135,
211,
444],
w
h
ich
h
as
placed
clon
ed
ch
an
n
els
in
to
groups
based
on
gen
e
fam
ily
an
d
structure
of
ch
an
n
els
th
at
exh
ibit
6,
4
or
2
tran
sm
em
bran
e
do-
m
ain
s
(TM
).
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C
alcium
-and
sodium
-activated
potassium
channels
V
oltage-gated
ion
ch
an
n
els→
Potassium
ch
an
n
els→
C
alcium
-an
d
sodium
-activated
potassium
ch
an
n
els
O
verview
:Th
e
6TM
fam
ily
ofK
ch
an
n
els
com
prises
th
e
voltage-gated
K
V
subfam
ilies,in
cludin
g
th
e
K
C
N
Q
subfam
ily,th
e
EA
G
subfam
ily
(w
h
ich
in
cludes
h
erg
ch
an
n
els),th
e
C
a 2+-activated
Slo
subfam
ily
(actually
w
ith
6
or7TM
)an
d
th
e
C
a 2+-an
d
N
a +-activated
SK
subfam
ily
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
C
alciu
m
-an
d
so
d
iu
m
-activated
p
o
tassiu
m
ch
an
n
els
[181]).A
s
for
th
e
2TM
fam
ily,th
e
pore-form
in
g
a
subun
its
form
tetram
ers
an
d
h
eterom
eric
ch
an
n
els
m
ay
be
form
ed
w
ith
in
subfam
ilies
(e.g.K
V
1.1
w
ith
K
V
1.2;K
C
N
Q
2
w
ith
K
C
N
Q
3).
N
om
enclature
K
C
a 1.1
K
C
a 2.1
K
C
a 2.2
K
C
a 2.3
K
C
a 3.1
H
G
N
C
,U
niProt
KCN
M
A1,Q
12791
KCN
N
1,Q
92952
KCN
N
2,Q
9H
2S1
KCN
N
3,Q
9U
G
I6
KCN
N
4,O
15554
Activators
N
S004,N
S1619
EBIO
C
oncentration
range:2×
10 −
3M
[-80m
V][320,442],N
S309
C
oncentration
range:
3×
10 −
8M
-1×
10 −
7M
[-90m
V][388,442]
N
S309
(pEC
50
6.2)
C
oncentration
range:3×
10 −
8M
-1×
10 −
7M
[319,
388,442],EBIO
(pEC
50
3.3)
[319,
442],EBIO
(pEC
50
3)
C
oncentration
range:2×
10 −
3M
[48,320]–
Rat
EBIO
(pEC
50
3.8)
[442,450],
N
S309
C
oncentration
range:
3×
10 −
8M
[388,442]
N
S309
(pEC
50
8)
[-90m
V][388,
442],SKA-121
(pEC
50
7)
[72],
EBIO
(pEC
50
4.1–4.5)
[-100m
V
–
-50m
V][320,394,442]
Inhibitors
paxilline
(pK
i 8.7)
[0m
V]
[360]–
M
ouse
U
C
L1684
(pIC
50
9.1)
[387,442],apam
in
(pIC
50
7.9–8.5)
[367,385,387]
U
C
L1684
(pIC
50
9.6)
[103,442],
apam
in
(pK
d
9.4)
[180]
apam
in
(pIC
50
7.9–9.1)
[407,
450],U
C
L1684
(pIC
50
8–9)
[103,442]
TRAM
-34
(pK
d
7.6–8)
[213,456]
C
hannelblockers
charybdotoxin,iberiotoxin,
tetraethylam
m
onium
tetraethylam
m
onium
(pIC
50
2.7)
[442]
tetraethylam
m
onium
(pIC
50
2.7)
[442]
tetraethylam
m
onium
(pIC
50
2.7)
[442]
charybdotoxin
(pIC
50
7.6–8.7)
[171,176]
Functional
C
haracteristics
M
axiK
C
a
SK
C
a
SK
C
a
SK
C
a
IK
C
a
C
om
m
ents
–
The
rat
isoform
does
not
form
functional
channels
w
hen
expressed
alone
in
cell
lines.N
-or
C
-term
inalchim
eric
constructs
perm
it
functionalchannels
that
are
insensitive
to
apam
in
[442].
H
eterom
eric
channels
are
form
ed
betw
een
K
C
a 2.1
and
2.2
subunits
that
show
interm
ediate
sensitivity
to
apam
in
[68].
–
–
–
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N
om
enclature
K
N
a 1.1
K
N
a 1.2
K
C
a 5.1
H
G
N
C
,U
niProt
KCN
T1,Q
5JU
K3
KCN
T2,Q
6U
VM
3
KCN
U
1,A8M
YU
2
Activators
bithionol(pEC
50
5–6)
[470]–
Rat,niclosam
ide
(pEC
50
5.5)
[32],loxapine
(pEC
50
5.4)
[32]
niflum
ic
acid
(pEC
50
8.7)
[78,115]
–
G
ating
inhibitors
bepridil(pIC
50
5–6)
[470]–
Rat
–
–
C
hannelblockers
quinidine
(pIC
50
4)
[29,470]–
Rat
Ba 2+
(pIC
50
3)
[29],quinidine
C
oncentration
range:
1×
10 −
3M
[29]–
Rat
quinidine
C
oncentration
range:2×
10 −
5M
[404,454]
–
M
ouse
FunctionalC
haracteristics
K
N
a
K
N
a
Sperm
pH
-regulated
K
+
current,KSPER
Inw
ardly
rectifying
potassium
channels
V
oltage-gated
ion
ch
an
n
els→
Potassium
ch
an
n
els→
In
w
ardly
rectifyin
g
potassium
ch
an
n
els
O
verview
:
Th
e
2TM
dom
ain
fam
ily
of
K
ch
an
n
els
are
also
kn
ow
n
as
th
e
in
w
ard-rectifier
K
ch
an
n
el
fam
ily.
Th
is
fam
ily
in
cludes
th
e
stron
g
in
w
ard-rectifier
K
ch
an
n
els
(K
ir 2.x)
th
at
are
con
stitutively
active,th
e
G
-protein
-activated
in
w
ard-rectifier
K
ch
an
n
els
(K
ir 3.x)
an
d
th
e
A
TP-sen
sitive
K
ch
an
n
els
(K
ir 6.x,w
h
ich
com
bin
e
w
ith
sulph
on
ylurea
receptors
(SU
R
1-3)).
Th
e
pore-form
in
g
α
subun
its
form
tetram
ers,an
d
h
eterom
eric
ch
an
n
els
m
ay
be
form
ed
w
ith
in
subfam
ilies
(e.g.K
ir 3.2
w
ith
K
ir 3.3).
N
om
enclature
K
ir 1.1
H
G
N
C
,U
niProt
KCN
J1,P48048
Ion
Selectivity
and
C
onductance
N
H
4
+
[62pS]>
K
+
[38.pS]>
Tl +
[21pS]>
Rb
+
[15pS](Rat)
[62,150]
C
hannelblockers
tertiapin-Q
(pIC
50
8.9)
[175],Ba 2+
(pIC
50
2.3–4.2)
C
oncentration
range:1×
10 −
4M
[voltage
dependent0m
V
–
-100m
V][150,484]–
Rat,C
s +
(pIC
50
2.9)
[voltage
dependent-120m
V][484]–
Rat
FunctionalC
haracteristics
K
ir 1.1
is
w
eakly
inw
ardly
rectifying,as
com
pared
to
classical(strong)
inw
ard
rectifiers.
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(continued)
N
om
enclature
K
ir 2.1
K
ir 2.2
K
ir 2.3
K
ir 2.4
H
G
N
C
,U
niProt
KCN
J2,P63252
KCN
J12,Q
14500
KCN
J4,P48050
KCN
J14,Q
9U
N
X
9
Endogenous
activators
PIP
2
C
oncentration
range:
1×
10 −
5M
-5×
10 −
5M
[-30m
V][158,
348,379]–
M
ouse
–
–
–
Endogenous
inhibitors
–
Intracellular
M
g
2+
(pIC
50
5)
[40m
V][469]
–
Intracellular
M
g
2+
G
ating
inhibitors
–
Ba 2+
C
oncentration
range:5×
10 −
5M
[-150m
V
–
-50m
V]
[397]–
M
ouse,C
s +
C
oncentration
range:
5×
10 −
6M
-5×
10 −
5M
[-150m
V
–
-50m
V][397]–
M
ouse
–
–
Endogenous
channelblockers
sperm
ine
(pK
d
9.1)
[voltage
dependent40m
V][167,471]–
M
ouse,sperm
idine
(pK
d
8.1)
[voltage
dependent40m
V][471]–
M
ouse,putrescine
(pK
d
5.1)
[voltage
dependent40m
V][167,
471]–
M
ouse,Intracellular
M
g
2+
(pK
d
4.8)
[voltage
dependent
40m
V][471]–
M
ouse
–
Intracellular
M
g
2+
(pK
d
5)
[voltage
dependent50m
V][246],
putrescine
C
oncentration
range:
5×
10 −
5M
-1×
10 −
3M
[-80m
V
–
80m
V][246],sperm
idine
C
oncentration
range:
2.5×
10 −
5M
-1×
10 −
3M
[-80m
V
–
80m
V][246],sperm
ine
C
oncentration
range:
5×
10 −
5M
-1×
10 −
3M
[-80m
V
–
80m
V][246]
C
hannelblockers
Ba 2+
(pK
d
3.9–5.6)
C
oncentration
range:1×
10 −
6M
-1×
10 −
4M
[voltage
dependent0m
V
–
-80m
V]
[6]–
M
ouse,C
s +
(pK
d
1.3–4)
C
oncentration
range:
3×
10 −
5M
-3×
10 −
4M
[voltage
dependent0m
V
–
-102m
V][3]–
M
ouse
–
Ba 2+
(pIC
50
5)
C
oncentration
range:3×
10 −
6M
-5×
10 −
4M
[-60m
V][260,335,405],C
s +
(pK
i
1.3–4.5)
C
oncentration
range:
3×
10 −
6M
-3×
10 −
4M
[0m
V
–
-130m
V][260]
C
s +
(pK
d
3–4.1)
[voltage
dependent
-100m
V
–
-60m
V][159],Ba 2+
(pK
d
3.3)
[voltage
dependent0m
V][159]
FunctionalC
haracteristics
IK
1
in
heart,‘strong’
inw
ard–rectifier
current
IK
1
in
heart,‘strong’inw
ard–rectifier
current
IK
1
in
heart,‘strong’
inw
ard–rectifier
current
IK
1
in
heart,‘strong’
inw
ard–rectifier
current
C
om
m
ents
K
ir 2.1
is
also
inhibited
by
intracellular
polyam
ines
K
ir 2.2
is
also
inhibited
by
intracellular
polyam
ines
K
ir 2.3
is
also
inhibited
by
intracellular
polyam
ines
K
ir 2.4
is
also
inhibited
by
intracellular
polyam
ines
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(continued)
N
om
enclature
K
ir 3.1
K
ir 3.2
K
ir 3.3
K
ir 3.4
H
G
N
C
,U
niProt
KCN
J3,P48549
KCN
J6,P48051
KCN
J9,Q
92806
KCN
J5,P48544
Endogenous
activators
PIP
2
(pK
d
6.3)
C
oncentration
range:5×
10 −
5M
[physiologicalvoltage][158]
PIP
2
(pK
d
6.3)
C
oncentration
range:
5×
10 −
5M
[physiologicalvoltage][158]
PIP
2
[145]
PIP
2
[20,145]
G
ating
inhibitors
–
pim
ozide
(D
ata
obtained
using
K
ir 3.1/3.2
heterom
er)
(pEC
50
5.5)
[-70m
V][201]–
M
ouse
–
–
C
hannelblockers
tertiapin-Q
(K
ir 3.1/3.4;expression
in
Xenopus
oocytes)
(pIC
50
7.9)
[174],Ba 2+
(K
ir 3.1
expressed
in
Xenopus
oocytes)
(pIC
50
4.7)
[80]–
Rat
desipram
ine
(D
ata
obtained
using
K
ir 3.1/3.2
heterom
er)
(pIC
50
4.4)
[-70m
V]
[202]–
M
ouse
–
tertiapin-Q
(K
ir 3.1/3.4)
(pIC
50
7.9)
[174]
FunctionalC
haracteristics
G
protein-activated
inw
ard-rectifier
current
G
protein-activated
inw
ard-rectifier
current
G
protein-activated
inw
ard-rectifier
current
G
protein-activated
inw
ard-rectifier
current
C
om
m
ents
K
ir 3.1
is
also
activated
by
G
βγ .K
ir 3.1
is
not
functionalalone.
The
functionalexpression
ofK
ir 3.1
in
Xenopus
oocytes
requires
coassem
bly
w
ith
the
endogenous
Xenopus
K
ir 3.5
subunit.The
m
ajor
functionalassem
bly
in
the
heart
is
the
K
ir 3.1/3.4
heterom
ultim
er,w
hile
in
the
brain
it
is
K
ir 3.1/3.2,
K
ir 3.1/3.3
and
K
ir 3.2/3.3.
K
ir 3.2
is
also
activated
by
G
βγ .K
ir 3.2
form
s
functionalheterom
ers
w
ith
K
ir 3.1/3.3.
K
ir 3.3
is
also
activated
by
G
βγ
K
ir 3.4
is
also
activated
by
G
βγ
N
om
enclature
K
ir 4.1
K
ir 4.2
K
ir 5.1
H
G
N
C
,U
niProt
KCN
J10,P78508
KCN
J15,Q
99712
KCN
J16,Q
9N
PI9
C
hannelblockers
Ba 2+
C
oncentration
range:3×
10 −
6M
-1×
10 −
3M
[-160m
V
–
60m
V][205,399,403]–
Rat,C
s +
C
oncentration
range:
3×
10 −
5M
-3×
10 −
4M
[-160m
V
–
50m
V][399]–
Rat
Ba 2+
(K
ir 4.2
expressed
in
Xenopus
oocytes)
C
oncentration
range:1×
10 −
5M
-1×
10 −
4M
[-120m
V
–
100m
V][318]–
M
ouse,C
s +
(K
ir 4.2
expressed
in
Xenopus
oocytes)
C
oncentration
range:1×
10 −
5M
-1×
10 −
4M
[-120m
V
–
100m
V][318]–
M
ouse
Ba 2+
(K
ir 5.1
expressed
w
ith
PSD
-95)
C
oncentration
range:3×
10 −
3M
[-120m
V
–
20m
V][402]–
Rat
FunctionalC
haracteristics
Inw
ard-rectifier
current
Inw
ard-rectifier
current
W
eakly
inw
ardly
rectifying
Searchable
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N
om
enclature
K
ir 6.1
K
ir 6.2
K
ir 7.1
H
G
N
C
,U
niProt
KCN
J8,Q
15842
KCN
J11,Q
14654
KCN
J13,O
60928
Associated
subunits
SU
R1,SU
R2A,SU
R2B
SU
R1,SU
R2A,SU
R2B
–
Activators
crom
akalim
,diazoxide
C
oncentration
range:2×
10 −
4M
[-60m
V][466]–
M
ouse,m
inoxidil,nicorandil
C
oncentration
range:3×
10 −
4M
[-60m
V
–
60m
V][466]–
M
ouse
diazoxide
(pEC
50
4.2)
[physiologicalvoltage][162]–
M
ouse,crom
akalim
C
oncentration
range:3×
10 −
5M
[-60m
V][163]–
M
ouse,m
inoxidil,nicorandil
–
Inhibitors
glibenclam
ide,tolbutam
ide
glibenclam
ide,tolbutam
ide
–
C
hannelblockers
–
–
Ba 2+
(pK
i 3.2)
[voltage
dependent-100m
V][99,210,
212,311],C
s +
(pK
i 1.6)
[voltage
dependent-100m
V]
[99,210,311]
FunctionalC
haracteristics
ATP-sensitive,inw
ard-rectifier
current
ATP-sensitive,inw
ard-rectifier
current
Inw
ard-rectifier
current
Tw
o
P
dom
ain
potassium
channels
V
oltage-gated
ion
ch
an
n
els→
Potassium
ch
an
n
els→
Tw
o
P
dom
ain
potassium
ch
an
n
els
O
verview
:
Th
e
4TM
fam
ily
of
K
ch
an
n
els
m
ediate
m
an
y
of
th
e
backgroun
d
potassium
curren
ts
observed
in
n
ative
cells.Th
ey
are
open
across
th
e
ph
ysiologicalvoltage-ran
ge
an
d
are
regulated
by
a
w
ide
array
of
n
eurotran
sm
itters
an
d
bioch
em
ical
m
ediators.
Th
e
pore-form
in
g
α
-subun
it
con
tain
s
tw
o
pore
loop
(P)
dom
ain
s
an
d
tw
o
subun
its
assem
ble
to
form
on
e
ion
con
duction
path
w
ay
lin
ed
by
four
P
dom
ain
s.Itis
im
portan
t
to
n
ote
th
at
sin
gle
ch
an
n
els
do
n
oth
ave
tw
o
pores
butth
ateach
subun
ith
as
tw
o
P
dom
ain
s
in
its
prim
ary
sequen
ce;
h
en
ce
th
e
n
am
e
tw
o
P
dom
ain
,
or
K
2P
ch
an
-
n
els
(an
d
n
ot
tw
o-pore
ch
an
n
els).
Som
e
of
th
e
K
2P
subun
its
can
form
h
eterodim
ers
across
subfam
ilies
(e.g.
K
2P 3.1
w
ith
K
2P 9.1).
Th
e
n
om
en
clature
of
4TM
K
ch
an
n
els
in
th
e
literature
is
still
a
m
ixture
of
IU
PH
A
R
an
d
com
m
on
n
am
es.
Th
e
suggested
division
in
to
subfam
ilies,below
,is
based
on
sim
ilarities
in
both
structural
an
d
fun
ction
alproperties
w
ith
in
subfam
ilies.
N
om
enclature
K
2P 1.1
K
2P 2.1
K
2P 3.1
K
2P 4.1
H
G
N
C
,U
niProt
KCN
K1,O
00180
KCN
K2,O
95069
KCN
K3,O
14649
KCN
K4,Q
9N
YG
8
Endogenous
activators
–
arachidonic
acid
(studied
at
1-10
µ
M
)
(pEC
50
5)
[314]
–
arachidonic
acid
(studied
at
1-10
µ
M
)
[108]
Activators
–
chloroform
(studied
at
1-5
m
M
)
C
oncentration
range:8×
10 −
3M
[313],
halothane
(studied
at
1-5
m
M
)
[313],
isoflurane
(studied
at
1-5
m
M
)
[313]
halothane
(studied
at
1-10
m
M
)
riluzole
(studied
at
1-100
µ
M
)
[97]
C
hannelblockers
–
–
R-(+)-m
ethanandam
ide
(pIC
50 ∼
6.2)
[257],anandam
ide
(pIC
50 ∼
6.2)
[257]
–
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N
om
enclature
K
2P 1.1
K
2P 2.1
K
2P 3.1
K
2P 4.1
FunctionalC
haracteristics
Background
current
Background
current
Background
current
Background
current
C
om
m
ents
K
2P 1.1
is
inhibited
by
acid
pH
o
externalacidification
w
ith
a
pK
a ˜
6.7
[331].K
2P 1
form
s
heterodim
ers
w
ith
K
2P 3
and
K
2P 9
[332].
K
2P 2.1
is
also
activated
by
m
em
brane
stretch,heat
and
acid
pH
i [256,258].
K
2P 2
can
heterodim
erize
w
ith
K
2P 4
[33]and
K
2P 10
[228].
Knock-out
ofthe
kcnk3
gene
leads
to
a
prolonged
Q
T
intervalin
m
ice
[83]and
disrupted
developm
ent
ofthe
adrenalcortex
[143].K
2P 3.1
is
inhibited
by
acid
pH
o
w
ith
a
pK
a
of6.4
[247].K
2P 3
form
s
heterodim
ers
w
ith
K
2P 1
[332]and
K
2P 9
[77].
K
2P 4
is
activated
by
m
em
brane
stretch
[255],and
increased
tem
perature
(˜12
to
20-fold
betw
een
17
and
40°C
[183])
and
can
heterodim
erize
w
ith
K
2P 2
[33].
N
om
enclature
K
2P 5.1
K
2P 6.1
K
2P 7.1
K
2P 9.1
H
G
N
C
,U
niProt
KCN
K5,O
95279
KCN
K6,Q
9Y257
KCN
K7,Q
9Y2U
2
KCN
K9,Q
9N
PC
2
Activators
–
–
–
halothane
(studied
at
1-5
m
M
)
[401]
Inhibitors
–
–
–
R-(+)-m
ethanandam
ide
(studied
at
1-10
µ
M
)
[343],anandam
ide
(studied
at
1-10
µ
M
)
[343]
FunctionalC
haracteristics
Background
current
U
nknow
n
U
nknow
n
Background
current
C
om
m
ents
K
2P 5.1
is
activated
by
alkaline
pH
o
[351].Knockout
ofthe
kcnk5
gene
in
m
ice
is
associated
w
ith
m
etabolic
acidosis,hyponatrem
ia
and
hypotension
due
to
im
paired
bicarbonate
handling
in
the
kidney
[441],
as
w
ellas
deafness
[55].The
T108P
m
utation
is
associated
w
ith
Balkan
Endem
ic
N
ephropathy
in
hum
ans
[414].
–
–
K
2P 9.1
is
also
inhibited
by
acid
pH
o
w
ith
a
pK
a
of˜
6
[343].Im
printing
ofthe
KCN
K9
gene
is
associated
w
ith
Birk
Barelsyndrom
e
[18].K
2P 9
can
form
heterodim
ers
w
ith
K
2P 1
[332]or
K
2P 3
[77].
N
om
enclature
K
2P 10.1
K
2P 12.1
K
2P 13.1
K
2P 15.1
K
2P 16.1
K
2P 17.1
K
2P 18.1
H
G
N
C
,U
niProt
KCN
K10,P57789
KCN
K12,Q
9H
B15
KCN
K13,
Q
9H
B14
KCN
K15,
Q
9H
427
KCN
K16,Q
96T55
KCN
K17,Q
96T54
KCN
K18,Q
7Z418
Endogenous
activators
arachidonic
acid
(studied
at
1-10
µ
M
)
[225]
–
–
–
–
–
–
Activators
halothane
(studied
at
1-5
m
M
)
[225]
–
–
–
–
–
–
Endogenous
inhibitors
–
–
–
–
–
–
arachidonic
acid
(studied
at
10-50
µ
M
)
[361]
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N
om
enclature
K
2P 10.1
K
2P 12.1
K
2P 13.1
K
2P 15.1
K
2P 16.1
K
2P 17.1
K
2P 18.1
Inhibitors
norfluoxetine
(pIC
50
5.1)
[189]
–
halothane
(studied
at˜5
m
M
)
[34]
–
–
–
–
FunctionalC
haracteristics
Background
current
D
oes
not
function
as
a
hom
odim
er
[342]but
can
form
a
functional
heterodim
er
w
ith
K
2P 13
[34].
Background
current
U
nknow
n
Background
current
Background
current
Background
current
C
om
m
ents
K
2P 10.1
is
also
activated
by
m
em
brane
stretch
[225]
and
can
heterodim
erize
w
ith
K
2P 2
[228].
–
Form
s
a
heterodim
er
w
ith
K
2P 12
[34].
–
K
2P 16.1
current
is
increased
by
alkaline
pH
o
w
ith
a
pK
a
of7.8
[184].
K
2P 17.1
current
is
increased
by
alkaline
pH
o
w
ith
a
pK
a
of8.8
[184].
A
fram
e-shift
m
utation
(F139W
fsX
24)
in
the
KCN
K18
gene,is
associated
w
ith
m
igraine
w
ith
aura
in
hum
ans
[214].
C
o
m
m
en
ts:
Th
e
K
2P 6,
K
2P 7.1,
K
2P 15.1
an
d
K
2P 12.1
subtypes,
w
h
en
expressed
in
isolation
,
are
n
on
fun
ction
al.
A
ll
4TM
ch
an
n
els
are
in
sen
sitive
to
th
e
classical
potassium
ch
an
n
el
blockers
tetraeth
ylam
m
on
ium
an
d
fam
pridin
e,but
are
blocked
to
varyin
g
degrees
by
Ba 2+
ion
s.
Voltage-gated
potassium
channels
V
oltage-gated
ion
ch
an
n
els→
Potassium
ch
an
n
els→
V
oltage-gated
potassium
ch
an
n
els
O
verview
:Th
e
6TM
fam
ily
of
K
ch
an
n
els
com
prises
th
e
voltage-gated
K
V
subfam
ilies,th
e
EA
G
subfam
ily
(w
h
ich
in
cludes
h
ER
G
ch
an
n
els),th
e
C
a 2+-activated
Slo
subfam
ily
(actually
w
ith
7TM
,term
ed
BK
)
an
d
th
e
C
a 2+-activated
SK
subfam
ily.Th
ese
ch
an
n
els
possess
a
pore-form
in
g
α
subun
it
th
at
com
prise
tetram
ers
of
iden
ticalsubun
its
(h
om
om
eric)
or
of
differen
t
subun
its
(h
eterom
eric).H
eterom
eric
ch
an
n
els
can
on
ly
be
form
ed
w
ith
in
subfam
ilies
(e.g.K
v 1.1
w
ith
K
v 1.2;K
v 7.2
w
ith
K
v 7.3).Th
e
ph
arm
acology
largely
reflects
th
e
subun
it
com
position
of
th
e
fun
ction
alch
an
n
el.
N
om
enclature
K
v 1.1
K
v 1.2
K
v 1.3
K
v 1.4
H
G
N
C
,U
niProt
KCN
A1,Q
09470
KCN
A2,P16389
KCN
A3,P22001
KCN
A4,P22459
Associated
subunits
K
v 1.2,K
v 1.4,K
v β1
and
K
v β2
[73]
K
v 1.1,K
v 1.4,K
v
β1
and
K
v
β2
[73]
K
v 1.1,K
v 1.2,K
v 1.4,K
v 1.6
,K
v
β1
and
K
v
β2
[73]
K
v 1.1,K
v 1.2,K
v β1
and
K
v β2
[73]
C
hannelblockers
α
-dendrotoxin
(pEC
50
7.7–9)
[128,160]–
Rat,m
argatoxin
(pIC
50
8.4)
[19],
tetraethylam
m
onium
(pK
d
3.5)
[128]–
M
ouse
m
argatoxin
(pIC
50
11.2)
[19],α
-dendrotoxin
(pIC
50
7.8–9.4)
[128,160]–
Rat,noxiustoxin
(pK
d
8.7)
[128]–
Rat
m
argatoxin
(pIC
50
10–10.3)
[113,117],
noxiustoxin
(pK
d
9)
[128]–
M
ouse,
m
aurotoxin
(pIC
50
6.8)
[352],
tetraethylam
m
onium
(pK
d
2)
[128]–
M
ouse
fam
pridine
(pIC
50
1.9)
[391]–
Rat
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N
om
enclature
K
v 1.1
K
v 1.2
K
v 1.3
K
v 1.4
Selective
channel
blockers
–
–
correolide
(pIC
50
7.1)
[106]
–
FunctionalC
haracteristics
K
V
K
V
K
V
K
A
C
om
m
ents
–
–
Resistant
to
dendrotoxins
Resistant
to
dendrotoxins
N
om
enclature
K
v 1.5
K
v 1.6
K
v 1.7
K
v 1.8
H
G
N
C
,U
niProt
KCN
A5,P22460
KCN
A6,P17658
KCN
A7,Q
96RP8
KCN
A10,Q
16322
Associated
subunits
K
v
β1
and
K
v
β2
K
v
β1
and
K
v
β2
K
v
β1
and
K
v
β2
K
v
β1
and
K
v
β2
C
hannelblockers
fam
pridine
(pIC
50
4.3)
[105]
α
-dendrotoxin
(pIC
50
7.7)
[129],
tetraethylam
m
onium
(pIC
50
2.2)
[129]
noxiustoxin
(pIC
50
7.7)
[182]–
M
ouse,
fam
pridine
(pIC
50
3.6)
[182]–
M
ouse
fam
pridine
(pIC
50
2.8)
[217]
FunctionalC
haracteristics
K
v
K
V
K
V
K
V
C
om
m
ents
Resistant
to
externalTEA
–
–
–
N
om
enclature
K
v 2.1
K
v 2.2
K
v 3.1
K
v 3.2
K
v 3.3
K
v 3.4
H
G
N
C
,U
niProt
KCN
B1,Q
14721
KCN
B2,Q
92953
KCN
C1,P48547
KCN
C2,Q
96PR1
KCN
C3,Q
14003
KCN
C4,Q
03721
Associated
subunits
K
v 5.1,K
v 6.1-6.4,
K
v 8.1-8.2
and
K
v 9.1-9.3
K
v 5.1,K
v 6.1-6.4,K
v 8.1-8.2
and
K
v 9.1-9.3
–
–
–
M
iRP2
is
an
associated
subunit
for
K
v 3.4
C
hannelblockers
tetraethylam
m
onium
(pIC
50
2)
[142]–
Rat
fam
pridine
(pIC
50
2.8)
[363],tetraethylam
m
onium
(pIC
50
2.6)
[363]
fam
pridine
(pIC
50
4.5)
[128]–
M
ouse,tetraethylam
m
onium
(pIC
50
3.7)
[128]–
M
ouse
fam
pridine
(pIC
50
4.6)
[233]
–
Rat,tetraethylam
m
onium
(pIC
50
4.2)
[233]–
Rat
tetraethylam
m
o-
nium
(pIC
50
3.9)
[419]–
Rat
tetraethylam
m
onium
(pIC
50
3.5)
[350,365]–
Rat
Selective
channel
blockers
–
–
–
–
–
sea
anem
one
toxin
BD
S-I
(pIC
50
7.3)
[93]–
Rat
FunctionalC
haracteristics
K
V
–
K
V
K
V
K
A
K
A
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N
om
enclature
K
v 4.1
K
v 4.2
K
v 4.3
H
G
N
C
,U
niProt
KCN
D
1,Q
9N
SA2
KCN
D
2,Q
9N
ZV8
KCN
D
3,Q
9U
K17
Associated
subunits
KC
hIP
1-4,D
P66,D
PP10
KC
hIP
1-4,D
PP6,D
PP10,K
v β1,N
C
S-1,N
av β1
KC
hIP
1-4,D
PP6
and
D
PP10,M
inK,M
iRPs
C
hannelblockers
fam
pridine
(pIC
50
2)
[166]
–
–
FunctionalC
haracteristics
K
A
K
A
K
A
N
om
enclature
K
v 5.1
K
v 6.1
K
v 6.2
K
v 6.3
K
v 6.4
H
G
N
C
,U
niProt
KCN
F1,Q
9H
3M
0
KCN
G
1,Q
9U
IX
4
KCN
G
2,Q
9U
J96
KCN
G
3,Q
8TAE7
KCN
G
4,Q
8TD
N
1
N
om
enclature
K
v 7.1
K
v 7.2
K
v 7.3
K
v 7.4
K
v 7.5
H
G
N
C
,U
niProt
KCN
Q
1,P51787
KCN
Q
2,O
43526
KCN
Q
3,O
43525
KCN
Q
4,P56696
KCN
Q
5,Q
9N
R82
Activators
–
retigabine
(pEC
50
5.6)
[406]
retigabine
(pEC
50
6.2)
[406]
retigabine
(pEC
50
5.2)
[406]
retigabine
(pEC
50
5)
[98]
Inhibitors
X
E991
(pK
d
6.1)
[436],
linopirdine
(pIC
50
4.4)
[302]–
M
ouse
X
E991
(pIC
50
6.2)
[437],
linopirdine
(pIC
50
5.3)
[437],
linopirdine
(pIC
50
5.4)
[437]–
Rat
X
E991
(pIC
50
5.3)
[396],linopirdine
(pIC
50
4.9)
[396],
linopirdine
(pK
d
4.8)
[224],X
E991
(pIC
50
4.2)
[364]
C
hannelblockers
tetraethylam
m
onium
(pIC
50
3.5–3.9)
[136,446]
–
tetraethylam
m
onium
(pIC
50
1.3)
[13]
FunctionalC
haracteristics
cardiac
IK
5
M
current
as
a
heterom
er
betw
een
K
V 7.2
and
K
V 7.3
M
current
as
heterom
eric
K
V 7.2/K
V 7.3
or
K
V 7.3/K
V 7.5
–
M
current
as
heterom
eric
K
V 7.3/K
V 7.5
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N
om
enclature
K
v 8.1
K
v 8.2
K
v 9.1
K
v 9.2
K
v 9.3
K
v 10.1
K
v 10.2
H
G
N
C
,U
niProt
KCN
V1,Q
6PIU
1
KCN
V2,Q
8TD
N
2
KCN
S1,Q
96KK3
KCN
S2,Q
9U
LS6
KCN
S3,Q
9BQ
31
KCN
H
1,O
95259
KCN
H
5,Q
8N
C
M
2
N
om
enclature
K
v 11.1
K
v 11.2
K
v 11.3
K
v 12.1
K
v 12.2
K
v 12.3
H
G
N
C
,U
niProt
KCN
H
2,Q
12809
KCN
H
6,Q
9H
252
KCN
H
7,Q
9N
S40
KCN
H
8,Q
96L42
KCN
H
3,Q
9U
LD
8
KCN
H
4,Q
9U
Q
05
Associated
subunits
m
inK
(KC
N
E1)
and
M
iRP1
(KC
N
E2)
m
inK
(KC
N
E1)
m
inK
(KC
N
E1)
m
inK
(KC
N
E1)
m
inK
(KC
N
E1)
and
M
iRP2
(KC
N
E3)
–
C
hannelblockers
astem
izole
(pIC
50
9)
[486],terfenadine
(pIC
50
7.3)
[344],disopyram
ide
(pIC
50
4)
[190]
–
–
–
–
–
Inhibitor
E4031
(pIC
50
8.1)
[485]
–
–
–
–
–
Selective
channelblockers
dofetilide
(pK
i 8.2)
[372],ibutilide
(pIC
50
7.6–8)
[190,326]
–
–
–
–
–
FunctionalC
haracteristics
cardiac
IK
R
–
–
–
–
–
C
om
m
ents
RPR260243
is
an
activator
ofK
v 11.1
[185].
–
–
–
–
–
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con
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m
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Ryanodine
receptors
V
oltage-gated
ion
ch
an
n
els→
R
yan
odin
e
receptors
O
verview
:
Th
e
ryan
odin
e
receptors
(R
yR
s)
are
foun
d
on
in
-
tracellular
C
a 2+
storage/release
organ
elles.
Th
e
fam
ily
of
R
yR
gen
es
en
codes
th
ree
h
igh
ly
related
C
a 2+
release
ch
an
n
els:
R
yR
1,
R
yR
2
an
d
R
yR
3,
w
h
ich
assem
ble
as
large
tetram
eric
structures.
Th
ese
R
yR
ch
an
n
els
are
ubiquitously
expressed
in
m
an
y
types
of
cells
an
d
participate
in
a
variety
of
im
-
portan
t
C
a 2+
sign
alin
g
ph
en
om
en
a
(n
eurotran
sm
ission
,
se-
cretion
,
etc.).
In
addition
to
th
e
th
ree
m
am
m
alian
isoform
s
described
below
,
various
n
on
m
am
m
alian
isoform
s
of
th
e
ryan
odin
e
receptor
h
ave
been
iden
tified
[392].
Th
e
fun
c-
tion
of
th
e
ryan
odin
e
receptor
ch
an
n
els
m
ay
also
be
in
fluen
ced
by
closely
associated
protein
s
such
as
th
e
tacrolim
us
(FK
506)-bin
din
g
protein
,
calm
odulin
[467],
triadin
,
calsequestrin
,
jun
ctin
an
d
sorcin
,
an
d
by
protein
kin
ases
an
d
ph
osph
atases.
N
om
enclature
RyR1
RyR2
RyR3
H
G
N
C
,U
niProt
RYR1,P21817
RYR2,Q
92736
RYR3,Q
15413
Endogenous
activators
cytosolic
ATP
(endogenous;m
M
range),cytosolic
C
a 2+
(endogenous;µ
M
range),
lum
inalC
a 2+
(endogenous)
cytosolic
ATP
(endogenous;m
M
range),
cytosolic
C
a 2+
(endogenous;µ
M
range),
lum
inalC
a 2+
(endogenous)
cytosolic
ATP
(endogenous;m
M
range),
cytosolic
C
a 2+
(endogenous;µ
M
range)
Activators
caffeine
(pharm
acological;m
M
range),ryanodine
(pharm
acological;nM
-µ
M
range),suram
in
(pharm
acological;µ
M
range)
caffeine
(pharm
acological;m
M
range),
ryanodine
(pharm
acological;nM
-µ
M
range),suram
in
(pharm
acological;µ
M
range)
caffeine
(pharm
acological;m
M
range),
ryanodine
(pharm
acological;nM
-µ
M
range)
Endogenous
antagonists
cytosolic
C
a 2+
C
oncentration
range:>1×
10 −
4M
,cytosolic
M
g
2+
(m
M
range)
cytosolic
C
a 2+
C
oncentration
range:
>1×
10 −
3M
,cytosolic
M
g
2+
(m
M
range)
cytosolic
C
a 2+
C
oncentration
range:
>1×
10 −
3M
,cytosolic
M
g
2+
(m
M
range)
Antagonists
dantrolene
–
dantrolene
C
hannelblockers
procaine,ruthenium
red,ryanodine
C
oncentration
range:>1×
10 −
4M
procaine,ruthenium
red,ryanodine
C
oncentration
range:>1×
10 −
4M
ruthenium
red
FunctionalC
haracteristics
C
a 2+:(P
C
a /P
K
6˜)
single-channelconductance:90
pS
(50m
M
C
a 2+),770
pS
(200
m
M
K
+)
C
a 2+:(P
C
a /P
K 6)
single-channel
conductance:90
pS
(50m
M
C
a 2+),720
pS
(210
m
M
K
+)
C
a 2+:(P
C
a /PK
6)
single-channel
conductance:140
pS
(50m
M
C
a 2+),777
pS
(250
m
M
K
+)
C
om
m
ents
RyR1
is
also
activated
by
depolarisation
via
D
H
P
receptor,calm
odulin
at
low
cytosolic
C
a 2+
concentrations,C
aM
kinase
and
PKA;antagonised
by
calm
odulin
at
high
cytosolic
C
a 2+
concentrations
RyR2
is
also
activated
by
C
aM
kinase
and
PKA;antagonised
by
calm
odulin
at
high
cytosolic
C
a 2+
concentrations
RyR3
is
also
activated
by
calm
odulin
at
low
cytosolic
C
a 2+
concentrations;antagonised
by
calm
odulin
at
high
cytosolic
C
a 2+
concentrations
C
o
m
m
en
ts:Th
e
m
odulators
of
ch
an
n
elfun
ction
in
cluded
in
th
is
table
are
th
ose
m
ost
com
m
on
ly
used
to
iden
tify
ryan
odin
e-sen
sitive
C
a 2+
release
path
w
ays.N
um
erous
oth
er
m
odulators
of
ryan
odin
e
receptor/ch
an
n
elfun
ction
can
be
foun
d
in
th
e
review
s
listed
below
.
Th
e
absen
ce
of
a
m
odulator
of
a
particular
isoform
of
receptor
in
dicates
th
at
th
e
action
of
th
at
m
odulator
h
as
n
ot
been
determ
in
ed,
n
ot
th
at
it
is
w
ith
out
effect.
Th
e
poten
tialrole
of
cyclic
A
D
P
ribose
as
an
en
dogen
ous
regulator
of
ryan
odin
e
receptor
ch
an
n
els
is
con
troversial.
A
region
of
R
yR
likely
to
be
in
volved
in
ion
tran
slocation
an
d
selection
h
as
been
iden
tified
[112,479].
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read
in
g
o
n
R
yan
o
d
in
e
recep
to
rs
O
’Brien
F
et
al.
(2015)
Th
e
ryan
odin
e
receptor
provides
h
igh
th
rough
put
C
a2+-release
but
is
pre-
cisely
regulated
by
n
etw
orks
ofassociated
protein
s:a
focus
on
protein
s
relevan
t
to
ph
osph
ory-
lation
.Biochem
Soc
Trans
43
:426-33
[PM
ID
:26009186]
Sam
so
M
.(2017)
A
guide
to
th
e
3D
structure
of
th
e
ryan
odin
e
receptor
type
1
by
cryoEM
.
Protein
Sci26
:52-68
[PM
ID
:27671094]
V
an
Petegem
F.
(2015)
R
yan
odin
e
receptors:
allosteric
ion
ch
an
n
el
gian
ts.
J
M
ol
Biol
427
:
31-53
[PM
ID
:25134758]
Zalk
R
etal.(2017)
C
a2+
R
elease
C
h
an
n
els
Join
th
e
’R
esolution
R
evolution
’.Trends
Biochem
Sci42
:
543-555
[PM
ID
:28499500]
Transient
Receptor
Potentialchannels
V
oltage-gated
ion
ch
an
n
els→
Tran
sien
t
R
eceptor
Poten
tialch
an
n
els
O
verview
:
Th
e
TR
P
superfam
ily
ofch
an
n
els
(n
o
m
en
clatu
re
as
ag
reed
b
y
N
C
-IU
P
H
A
R
[70,455]),w
h
ose
foun
derm
em
beristh
e
D
rosophila
Trp
ch
an
n
el,
exists
in
m
am
m
als
as
six
fam
ilies;
TR
PC
,
TR
PM
,
TR
PV,TR
PA
,TR
PP
an
d
TR
PM
L
based
on
am
in
o
acid
h
om
ologies.
TR
P
subun
its
con
tain
six
putative
tran
sm
em
bran
e
dom
ain
s
an
d
assem
ble
as
h
om
o-
or
h
etero-tetram
ers
to
form
cation
selective
ch
an
n
els
w
ith
diverse
m
odes
ofactivation
an
d
varied
perm
eation
properties
(review
ed
by
[307]).
Establish
ed,
or
poten
tial,
ph
ysio-
logicalfun
ction
softh
e
in
dividualm
em
bersofth
e
TR
P
fam
iliesare
discussed
in
detailin
th
e
recom
m
en
ded
review
san
d
a
com
pilation
edited
by
Islam
[168].
Th
e
establish
ed,or
poten
tial,in
volvem
en
t
ofTR
P
ch
an
n
els
in
disease
is
review
ed
in
[196,288]an
d
[290],to-
geth
erw
ith
a
specialedition
ofBiochem
ica
etBiophysica
A
cta
on
th
e
subject
[288].
Th
e
ph
arm
acology
of
m
ost
TR
P
ch
an
n
els
is
poorly
developed
[455].
Broad
spectrum
agen
ts
are
listed
in
th
e
tables
alon
g
w
ith
m
ore
selective,or
recen
tly
recogn
ised,ligan
ds
th
at
are
flagged
by
th
e
in
clusion
of
a
prim
ary
referen
ce.
M
ost
TR
P
ch
an
-
n
els
are
regulated
by
ph
osph
oin
ostides
such
as
PtIn
s(4,5)P
2
an
d
IP
3
alth
ough
th
e
effects
reported
are
often
com
plex,
occasion
-
ally
con
tradictory,
an
d
likely
to
be
depen
den
t
upon
experim
en
-
talcon
dition
s,such
as
in
tracellular
A
TP
levels
(review
ed
by
[291,
353,
424]).
Such
regulation
is
gen
erally
n
ot
in
cluded
in
th
e
ta-
bles.W
h
en
th
erm
osen
sitivity
is
m
en
tion
ed,
it
refers
specifically
to
a
h
igh
Q
10
of
gatin
g,
often
in
th
e
ran
ge
of
10-30,
but
does
n
ot
n
ecessarily
im
ply
th
at
th
e
ch
an
n
el’s
fun
ction
is
to
act
as
a
’h
ot’or
’cold’sen
sor.In
gen
eral,th
e
search
for
TR
P
activators
h
as
led
to
m
an
y
claim
s
for
tem
perature
sen
sin
g,
m
ech
an
osen
sation
,
an
d
lipid
sen
sin
g.
A
ll
protein
s
are
of
course
sen
sitive
to
en
ergies
of
bin
din
g,
m
ech
an
ical
force,
an
d
tem
perature,
but
th
e
issue
is
w
h
eth
er
th
e
proposed
in
put
is
w
ith
in
a
ph
ysiologically
relevan
t
ran
ge
resultin
g
in
a
respon
se.
T
R
PA
(an
k
yrin
)
fam
ily
TR
PA
1
is
th
e
sole
m
am
m
alian
m
em
ber
ofth
is
group
(review
ed
by
[114]).
TR
PA
1
activation
of
sen
sory
n
euron
s
con
tribute
to
n
o-
ciception
[177,
266,
386].
Pun
gen
t
ch
em
icals
such
as
m
ustard
oil
(A
ITC
),
allicin
,
an
d
cin
n
am
aldeh
yde
activate
TR
PA
1
by
m
od-
ification
of
free
th
iol
groups
of
cystein
e
side
ch
ain
s,
especially
th
ose
located
in
its
am
in
o
term
in
us
[22,149,251,253].
A
lken
als
w
ith
α
,
β-un
saturated
bon
ds,
such
as
propen
al
(acrolein
),
bute-
n
al
(crotylaldeh
yde),
an
d
2-pen
ten
al
can
react
w
ith
free
th
iols
via
M
ich
ael
addition
an
d
can
activate
TR
PA
1.
H
ow
ever,
poten
cy
appearsto
w
eaken
ascarbon
ch
ain
len
gth
in
creases[11,22].C
ova-
len
t
m
odification
leads
to
sustain
ed
activation
of
TR
PA
1.
C
h
em
i-
cals
in
cludin
g
carvacrol,m
en
th
ol,an
d
localan
esth
etics
reversibly
activate
TR
PA
1
by
n
on
-covalen
t
bin
din
g
[186,
222,
460,
461].
TR
PA
1
is
n
ot
m
ech
an
osen
sitive
un
der
ph
ysiological
con
dition
s,
but
can
be
activated
by
cold
tem
peratures
[86,187].
Th
e
electron
cryo-EM
structure
of
TR
PA
1
[315]
in
dicates
th
at
it
is
a
6-TM
h
o-
m
otetram
er.Each
subun
itofth
e
ch
an
n
elcon
tain
s
tw
o
sh
ort‘pore
h
elices’poin
tin
g
in
to
th
e
ion
selectivity
filter,w
h
ich
isbig
en
ough
to
allow
perm
eation
of
partially
h
ydrated
C
a 2+
ion
s.
A
coiled-
coil
dom
ain
in
th
e
carboxy-term
in
al
region
form
s
th
e
cytoplas-
m
ic
stalk
of
th
e
ch
an
n
el,an
d
is
surroun
ded
by
16
an
kyrin
repeat
dom
ain
s,w
h
ich
are
speculated
to
in
terdigitate
w
ith
an
overlyin
g
h
elix-turn
-h
elix
an
d
putative
β-sh
eet
dom
ain
con
tain
in
g
cystein
e
residues
targeted
by
electroph
ilic
TR
PA
1
agon
ists.
Th
e
TR
P
do-
m
ain
,
a
h
elix
at
th
e
base
of
S6,
run
s
perpen
dicular
to
th
e
pore
h
elices
suspen
ded
above
th
e
an
kyrin
repeats
below
,w
h
ere
it
m
ay
con
tribute
to
regulation
of
th
e
low
er
pore.
Th
e
coiled-coil
stalk
m
ediates
bun
dlin
g
of
th
e
four
subun
its
th
rough
in
teraction
s
be-
tw
een
predicted
α
-h
elices
at
th
e
base
of
th
e
ch
an
n
el.
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N
om
enclature
TRPA1
H
G
N
C
,U
niProt
TRPA1,O
75762
C
hem
icalactivators
Isothiocyanates
(covalent)
and
1,4-dihydropyridines
(non-covalent)
Physicalactivators
C
ooling
(<
17°C
)
(disputed)
Activators
acrolein
(covalent)
(pEC
50
5.3)
[physiologicalvoltage][22],allicin
(covalent)
(pEC
50
5.1)
[physiologicalvoltage][23],#
9-tetrahydrocannabinol(non-covalent)
(pEC
50
4.9)
[-60m
V][177],nicotine
(non-covalent)
(pEC
50
4.8)
[-75m
V][400],thym
ol(non-covalent)
(pEC
50
4.7)
C
oncentration
range:6.2×
10 −
6M
-2.5×
10 −
5M
[220],U
RB597
(non-covalent)
(pEC
50
4.6)
[287],(-)-m
enthol(M
entholis
also
active
at
the
m
ouse
TRPA1,but
becom
es
inhibitory
at
>
100µ
M
)
(pEC
50
4–4.5)
[186,458],cinnam
aldehyde
(covalent)
(pEC
50
4.2)
[physiologicalvoltage][14]–
M
ouse,icilin
(non-covalent)
C
oncentration
range:1×
10 −
4M
[physiologicalvoltage][386]–
M
ouse
Selective
activators
chlorobenzylidene
m
alononitrile
(covalent)
(pEC
50
6.7)
[41],form
alin
(covalent.This
levelofactivity
is
also
observed
for
rat
TRPA1)
(pEC
50
3.4)
[253,266]–
M
ouse
C
hannelblockers
AP18
(pIC
50
5.5)
[328],ruthenium
red
(pIC
50
5.5)
[-80m
V][280]–
M
ouse,H
C
030031
(pIC
50
5.2)
[266]
FunctionalC
haracteristics
γ
=
87–100
pS;conducts
m
ono-and
di-valent
cations
non-selectively
(P
C
a /PN
a
=
0.84);outw
ard
rectification;activated
by
elevated
intracellular
C
a 2+
T
R
P
C
(can
o
n
ical)
fam
ily
M
em
bers
of
th
e
TR
PC
subfam
ily
(review
ed
by
[2,
8,
27,
31,
111,
194,
312,
337])
fall
in
to
th
e
subgroups
outlin
ed
below
.
TR
PC
2
is
a
pseudogen
e
in
h
um
an
s.
It
is
gen
erally
accepted
th
at
all
TR
PC
ch
an
n
els
are
activated
dow
n
stream
ofG
q/11 -coupled
receptors,or
receptortyrosin
e
kin
ases
(review
ed
by
[333,415,455]).A
com
pre-
h
en
sive
listin
g
of
G
-protein
coupled
receptors
th
at
activate
TR
PC
ch
an
n
els
is
given
in
[2].
H
etero-oligom
eric
com
plexes
of
TR
PC
ch
an
n
els
an
d
th
eir
association
w
ith
protein
s
to
form
sign
allin
g
com
plexes
are
detailed
in
[8]
an
d
[195].
TR
PC
ch
an
n
els
h
ave
fre-
quen
tly
been
proposed
to
act
as
store-operated
ch
an
n
els
(SO
C
s)
(or
com
pen
en
ts
of
m
ulim
eric
com
plexes
th
at
form
SO
C
s),
acti-
vated
by
depletion
of
in
tracellular
calcium
stores
(review
ed
by
[8,
61,
321,
334,
359,
475]).
H
ow
ever,
th
e
w
eigh
t
of
th
e
eviden
ce
is
th
at
th
ey
are
n
ot
directly
gated
by
con
ven
tion
alstore-operated
m
ech
an
ism
s,
as
establish
ed
for
Stim
-gated
O
rai
ch
an
n
els.
TR
PC
ch
an
n
els
are
n
ot
m
ech
an
ically
gated
in
ph
ysiologically
relevan
t
ran
ges
of
force.
A
ll
m
em
bers
of
th
e
TR
PC
fam
ily
are
blocked
by
2-A
PB
an
d
SK
F96365
[139,140].
A
ctivation
of
TR
PC
ch
an
n
els
by
lipids
is
discussed
by
[27].
T
R
P
C
1/C
4/C
5
su
b
g
ro
u
p
TR
PC
4/C
5
m
ay
be
distin
guish
ed
from
oth
erTR
P
ch
an
n
els
by
th
eir
poten
tiation
by
m
icrom
olar
con
cen
tration
s
of
La 3+.
TR
PC
2
is
a
pseudogen
e
in
h
um
an
s,
but
in
oth
er
m
am
m
als
appears
to
be
an
ion
ch
an
n
el
localized
to
m
icrovilli
of
th
e
vom
eron
asal
organ
.
It
is
required
for
n
orm
alsexualbeh
avior
in
respon
se
to
ph
erom
on
es
in
m
ice.
It
m
ay
also
fun
ction
in
th
e
m
ain
olfactory
epith
elia
in
m
ice
[236,304,305,472,473,474,487].
T
R
P
C
3/C
6/C
7
su
b
g
ro
u
p
A
ll
m
em
bers
are
activated
by
diacylglycerol
in
depen
den
t
of
pro-
tein
kin
ase
C
stim
ulation
[140].
N
om
enclature
TRPC
1
TRPC
2
TRPC
3
TRPC
4
H
G
N
C
,U
niProt
TRPC1,P48995
TRPC2,–
TRPC3,Q
13507
TRPC4,Q
9U
BN
4
C
hem
icalactivators
N
O
-m
ediated
cysteine
S-nitrosylation
D
iacylglycerol(SAG
,O
AG
,D
O
G
):strongly
inhibited
by
C
a 2+/C
aM
once
activated
by
D
AG
[380]
diacylglycerols
N
O
-m
ediated
cysteine
S-nitrosylation,
potentiation
by
extracellular
protons
Physicalactivators
m
em
brane
stretch
–
–
–
Endogenous
activators
–
Intracellular
C
a 2+
–
–
Activators
–
D
O
G
C
oncentration
range:1×
10 −
4M
[-80m
V][248]–
M
ouse,SAG
C
oncentration
range:1×
10 −
4M
[-80m
V][248]–
M
ouse
–
La 3+
(µ
M
range)
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N
om
enclature
TRPC
1
TRPC
2
TRPC
3
TRPC
4
C
hannelblockers
2-APB
[-70m
V][389],G
d
3+
C
oncentration
range:2×
10 −
5M
[-70m
V][487],La 3+
C
oncentration
range:1×
10 −
4M
[-70m
V][389]
2-APB
C
oncentration
range:5×
10 −
5M
[-70m
V
–
80m
V][248]–
M
ouse,U
73122
(m
ay
be
indirect)
C
oncentration
range:
1×
10 −
5M
–
M
ouse
G
d
3+
(pEC
50
7)
[-60m
V][137],
BTP2
(pIC
50
6.5)
[-80m
V][141],
Pyr3
(pIC
50
6.2)
[197],La 3+
(pIC
50
5.4)
[-60m
V][137],2-APB
(pIC
50
5)
[physiologicalvoltage]
[234],N
i 2+,SKF96365
M
L204
(pIC
50
5.5)
[269],La 3+
(m
M
range),SKF96365,niflum
ic
acid
C
oncentration
range:3×
10 −
5M
[-60m
V]
[432]–
M
ouse
FunctionalC
haracteristics
It
is
not
yet
clear
that
TRPC
1
form
s
a
hom
om
er.It
does
form
heterom
ers
w
ith
TRPC
4
and
TRPC
5
γ
=
42
pS
linear
single
channelconductance
in
150
m
M
sym
m
etricalN
a +
in
vom
eronasal
sensory
neurons.P
C
a /P
N
a
=
2.7;perm
eant
to
N
a +,C
s +,C
a 2+,but
not
N
M
D
G
[305,473]
γ
=
66
pS;conducts
m
ono
and
di-valent
cations
non-selectively
(P
C
a /P
N
a
=
1.6);m
onovalent
cation
current
suppressed
by
extracellular
C
a 2+;dual(inw
ard
and
outw
ard)
rectification
γ
=
30
–41
pS,conducts
m
ono
and
di-valent
cations
non-selectively
(P
C
a /P
N
a
=
1.1
–
7.7);dual(inw
ard
and
outw
ard)
rectification
N
om
enclature
TRPC
5
TRPC
6
TRPC
7
H
G
N
C
,U
niProt
TRPC5,Q
9U
L62
TRPC6,Q
9Y210
TRPC7,Q
9H
C
X
4
C
hem
icalactivators
N
O
-m
ediated
cysteine
S-nitrosylation
(disputed),potentiation
by
extracellular
protons
D
iacylglycerols
diacylglycerols
Physicalactivators
M
em
brane
stretch
M
em
brane
stretch
–
Endogenous
activators
intracellular
C
a 2+
(at
negative
potentials)
(pEC
50
6.2),
lysophosphatidylcholine
20-H
ETE,arachidonic
acid,lysophosphatidylcholine
–
Activators
G
d
3+
C
oncentration
range:1×
10 −
4M
,La 3+
(µ
M
range),Pb
2+
C
oncentration
range:5×
10 −
6M
,genistein
(independent
of
tyrosine
kinase
inhibition)
[452]
flufenam
ate,hyp
9
[226],hyperforin
[227]
–
C
hannelblockers
KB-R7943
(pIC
50
5.9)
[207],M
L204
(pIC
50 ∼
5)
[269],2-APB
(pIC
50
4.7)
[-80m
V][464],La 3+
C
oncentration
range:5×
10 −
3M
[-60m
V][178]–
M
ouse
G
d
3+
(pIC
50
5.7)[-60m
V][164]–
M
ouse,SKF96365
(pIC
50
5.4)
[-60m
V][164]–
M
ouse,La 3+
(pIC
50 ∼
5.2),am
iloride
(pIC
50
3.9)
[-60m
V][164]–
M
ouse,C
d
2+
(pIC
50
3.6)
[-60m
V][164]–
M
ouse,2-APB,AC
AA,G
sM
Tx-4,
Extracellular
H
+,KB-R7943,M
L9
2-APB,La 3+
C
oncentration
range:1×
10 −
4M
[-60m
V][303]–
M
ouse,SKF96365
C
oncentration
range:2.5×
10 −
5M
[-60m
V]
[303]–
M
ouse,am
iloride
FunctionalC
haracteristics
γ
=
41-63
pS;conducts
m
ono-and
di-valent
cations
non-selectively
(P
C
a /P
N
a
=
1.8
–
9.5);dualrectification
(inw
ard
and
outw
ard)
as
a
hom
om
er,outw
ardly
rectifying
w
hen
expressed
w
ith
TRPC
1
or
TRPC
4
γ
=
28-37
pS;conducts
m
ono
and
divalent
cations
w
ith
a
preference
for
divalents
(P
C
a /P
N
a
=
4.5–5.0);m
onovalent
cation
current
suppressed
by
extracellular
C
a 2+
and
M
g
2+,
dualrectification
(inw
ard
and
outw
ard),or
inw
ard
rectification
γ
=
25–75
pS;conducts
m
ono
and
divalent
cations
w
ith
a
preference
for
divalents
(P
C
a /
P
C
s
=
5.9);m
odest
outw
ard
rectification
(m
onovalent
cation
current
recorded
in
the
absence
ofextracellular
divalents);m
onovalent
cation
current
suppressed
by
extracellular
C
a 2+
and
M
g
2+
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
TransientReceptor
potentialchannels
S178
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13884/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Voltage-gated
ion
channels.British
JournalofPharm
acology
(2017)174,S160–S194
T
R
P
M
(m
elastatin
)
fam
ily
M
em
bers
of
th
e
TR
PM
subfam
ily
(review
ed
by
[109,
139,
321,
482])
fallin
to
th
e
five
subgroups
outlin
ed
below
.
T
R
P
M
1/M
3
su
b
g
ro
u
p
In
darkn
ess,
glutam
ate
released
by
th
e
ph
otoreceptors
an
d
O
N
-
bipolar
cells
bin
ds
to
th
e
m
etabotropic
glutam
ate
receptor
6
,
leadin
g
to
activation
of
G
o
.
Th
is
results
in
th
e
closure
of
TR
PM
1.
W
h
en
th
e
ph
otoreceptors
are
stim
ulated
by
ligh
t,
glu-
tam
ate
release
is
reduced,
an
d
TR
PM
1
ch
an
n
els
are
m
ore
ac-
tive,
resultin
g
in
cell
m
em
bran
e
depolarization
.
H
um
an
TR
PM
1
m
utation
s
are
associated
w
ith
con
gen
ital
station
ary
n
igh
t
blin
d-
n
ess
(C
SN
B),
w
h
ose
patien
ts
lack
rod
fun
ction
.
TR
PM
1
is
also
foun
d
m
elan
ocytes.
Isoform
s
of
TR
PM
1
m
ay
presen
t
in
m
elan
ocytes,
m
elan
om
a,
brain
,
an
d
retin
a.
In
m
elan
om
a
cells,
TR
PM
1
is
prevalen
t
in
h
igh
ly
dyn
am
ic
in
tracellular
vesicular
structures
[165,
298].TR
PM
3
(review
ed
by
[301])
exists
as
m
ul-
tiple
splice
varian
ts
four
of
w
h
ich
(m
TR
PM
3α
1,
m
TR
PM
3α
2,
h
TR
PM
3a
an
d
h
TR
PM
3
1325 )
h
ave
been
ch
aracterised
an
d
foun
d
to
differ
sign
ifican
tly
in
th
eir
bioph
ysical
properties.
TR
PM
3
is
expressed
in
som
atosen
sory
n
euron
s
an
d
m
ay
be
im
portan
t
in
developm
en
tofh
eath
yperalgesia
durin
g
in
flam
m
ation
.TR
PM
3
is
frequen
tly
coexpressed
w
ith
TR
PA
1
an
d
TR
PV
1
in
th
ese
n
euron
s.
TR
PM
3
is
expressed
in
pan
creatic
beta
cells
as
w
ell
as
brain
,
pi-
tuitary
glan
d,
eye,
kidn
ey,
an
d
adipose
tissue
[300,
408].
TR
PM
3
m
ay
con
tribute
to
th
e
detection
of
n
oxious
h
eat
[428].
T
R
P
M
2
TR
PM
2
is
activated
un
der
con
dition
s
of
oxidative
stress
(respira-
tory
burst
of
ph
agocytic
cells)
an
d
isch
em
ic
con
dition
s.
H
ow
-
ever,th
e
direct
activators
are
A
D
PR
(P)
an
d
calcium
.
A
s
for
m
an
y
ion
ch
an
n
els,PIP
2
m
ust
also
be
presen
t
(review
ed
by
[468]).
N
u-
m
erous
splice
varian
ts
of
TR
PM
2
exist
w
h
ich
differ
in
th
eir
ac-
tivation
m
ech
an
ism
s
[96].
Th
e
C
-term
in
al
dom
ain
con
tain
s
a
TR
P
m
otif,
a
coiled-coil
region
,
an
d
an
en
zym
atic
N
U
D
T9
h
o-
m
ologous
dom
ain
.
TR
PM
2
appears
n
ot
to
be
activated
by
N
A
D
,
N
A
A
D
,
or
N
A
A
D
P,
but
is
directly
activated
by
A
D
PR
P
(aden
osin
e-5’-O
-disph
osph
oribose
ph
osph
ate)
[417].
T
R
P
M
4/5
su
b
g
ro
u
p
TR
PM
4
an
d
TR
PM
5
h
ave
th
e
distin
ction
w
ith
in
all
TR
P
ch
an
n
els
of
bein
g
im
perm
eable
to
C
a 2+
[455].
A
splice
varian
t
of
TR
PM
4
(i.e.TR
PM
4b)
an
d
TR
PM
5
are
m
olecular
can
didates
for
en
doge-
n
ous
calcium
-activated
cation
(C
A
N
)
ch
an
n
els
[130].
TR
PM
4
is
active
in
th
e
late
ph
ase
of
repolarization
of
th
e
cardiac
ven
tricu-
lar
action
poten
tial.
TR
PM
4
en
h
an
ces
beta
adren
ergic-m
ediated
in
otropy.
M
utation
s
are
associated
w
ith
con
duction
defects
[170,
263,
381].
TR
PM
4
h
as
been
sh
ow
n
to
be
an
im
portan
t
regulator
of
C
a 2+
en
try
in
to
m
ast
cells
[420]
an
d
den
dritic
cell
m
igration
[17].
TR
PM
5
in
taste
receptor
cells
of
th
e
ton
gue
appears
essen
-
tial
for
th
e
tran
sduction
of
sw
eet,
am
in
o
acid
an
d
bitter
stim
uli
[235]
TR
PM
5
con
tributes
to
th
e
slow
afterdepolarization
of
layer
5
n
euron
s
in
m
ouse
prefron
talcortex
[223].
T
R
P
M
6/7
su
b
g
ro
u
p
TR
PM
6
an
d
7
com
bin
e
ch
an
n
el
an
d
en
zym
atic
activities
(‘ch
an
zym
es’).
Th
ese
ch
an
n
els
h
ave
th
e
un
usualproperty
of
per-
m
eation
by
divalen
t
(C
a 2+,M
g
2+,Zn
2+)an
d
m
on
ovalen
t
cation
s,
h
igh
sin
gle
ch
an
n
el
con
ductan
ces,
but
overall
extrem
ely
sm
all
in
w
ard
con
ductan
ce
w
h
en
expressed
to
th
e
plasm
a
m
em
bran
e.
Th
ey
are
in
h
ibited
by
in
tern
al
M
g
2+
at˜0.6
m
M
,aroun
d
th
e
free
level
of
M
g
2+
in
cells.
W
h
eth
er
th
ey
con
tribute
to
M
g
2+
h
om
e-
ostasis
is
a
con
ten
tious
issue.W
h
en
eith
er
gen
e
is
deleted
in
m
ice,
th
e
result
is
em
bryon
ic
leth
ality.
Th
e
C
-term
in
al
kin
ase
region
is
cleaved
un
der
un
kn
ow
n
stim
uli,
an
d
th
e
kin
ase
ph
osph
orylates
n
uclear
h
iston
es.
T
R
P
M
8
Is
a
ch
an
n
el
activated
by
coolin
g
an
d
ph
arm
acological
agen
ts
evokin
g
a
‘cool’
sen
sation
an
d
participates
in
th
e
th
erm
osen
sa-
tion
of
cold
tem
peratures
[24,71,90]review
ed
by
[200,244,277,
425].
N
om
enclature
TRPM
1
TRPM
2
TRPM
3
H
G
N
C
,U
niProt
TRPM
1,Q
7Z4N
2
TRPM
2,O
94759
TRPM
3,Q
9H
C
F6
Physicalactivators
–
H
eat˜35°C
heat
(Q
10
=
7.2
betw
een
15
-25°C
;Vriens
etal.,2011),hypotonic
cellsw
elling
[428]
Endogenous
activators
pregnenolone
sulphate
[216]
intracellular
cAD
PR
(pEC
50
5)
[-80m
V
–
-60m
V][26,204,410],
intracellular
AD
P
ribose
(pEC
50
3.9–4.4)
[-80m
V][325],
intracellular
C
a 2+
(perhaps
via
calm
odulin),H
2 O
2
C
oncentration
range:5×
10 −
7M
-5×
10 −
5M
[physiologicalvoltage][110,138,
209,376,443],m
em
brane
PIP
2
[416],arachidonic
acid
C
oncentration
range:1×
10 −
5M
-3×
10 −
5M
[physiologicalvoltage]
[138]
sphingosine
(pEC
50
4.9)
[physiologicalvoltage][127],
epipregnanolone
sulphate
[259],pregnenolone
sulphate
[429],
sphinganine
C
oncentration
range:2×
10 −
5M
[physiologicalvoltage]
[127]
Activators
–
G
EA
3162
nifedipine
G
ating
inhibitors
–
2-APB
C
oncentration
range:1×
10 −
4M
[physiologicalvoltage][464]
Endogenous
channelblockers
Zn
2+
(pIC
50
6)
Zn
2+
(pIC
50
6),extracellular
H
+
M
g
2+
C
oncentration
range:9×
10 −
3M
[-80m
V
–
80m
V][299]–
M
ouse,extracellular
N
a +
(TRPM
3α
2
only)
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N
om
enclature
TRPM
1
TRPM
2
TRPM
3
C
hannelblockers
–
2-APB
(pIC
50
6.1)
[-60m
V][411],AC
AA
(pIC
50
5.8)
[physiologicalvoltage][208],clotrim
azole
C
oncentration
range:
3×
10 −
6M
-3×
10 −
5M
[-60m
V
–
-15m
V][147],econazole
C
oncentration
range:3×
10 −
6M
-3×
10 −
5M
[-60m
V
–
-15m
V]
[147],flufenam
ic
acid
C
oncentration
range:5×
10 −
5M
-1×
10 −
3M
[-60m
V
–
-50m
V][146,411],m
iconazole
C
oncentration
range:
1×
10 −
5M
[-60m
V][411]
G
d
3+
C
oncentration
range:1×
10 −
4M
[-80m
V
–
80m
V][126,219],
La 3+
C
oncentration
range:1×
10 −
4M
[physiologicalvoltage][126,
219]
FunctionalC
haracteristics
C
onducts
m
ono-and
di-valent
cations
non-selectively,dual
rectification
(inw
ard
and
outw
ard)
γ
=
52-60
pS
at
negative
potentials,76
pS
at
positive
potentials;
conducts
m
ono-and
di-valent
cations
non-selectively
(P
C
a /P
N
a
=
0.6-0.7);non-rectifying;inactivation
at
negative
potentials;
activated
by
oxidative
stress
probably
via
PARP-1,PARP
inhibitors
reduce
activation
by
oxidative
stress,activation
inhibited
by
suppression
ofAPD
R
form
ation
by
glycohydrolase
inhibitors.
TRPM
3
1235 :γ
=
83
pS
(N
a +
current),65
pS
(C
a 2+
current);
conducts
m
ono
and
di-valent
cations
non-selectively
(P
C
a /P
N
a
=
1.6)
TRPM
3α
1:selective
for
m
onovalent
cations
(P
C
a /P
C
s ˜0.1);
TRPM
3α
2:conducts
m
ono-and
di-valent
cations
non-selectively
(P
C
a /P
C
s
=
1–10);
O
utw
ardly
rectifying
(m
agnitude
varies
betw
een
spice
variants)
N
om
enclature
TRPM
4
TRPM
5
TRPM
6
H
G
N
C
,U
niProt
TRPM
4,Q
8TD
43
TRPM
5,Q
9N
ZQ
8
TRPM
6,Q
9BX
84
EC
num
ber
–
–
2.7.11.1
O
ther
channelblockers
Intracellular
nucleotides
including
ATP,AD
P,
adenosine
5’-m
onophosphate
and
AM
P-PN
P
w
ith
an
IC
50
range
of1.3-1.9
µ
M
–
–
O
ther
chem
icalactivators
–
–
constitutively
active,activated
by
reduction
ofintracellular
M
g
2+
Physicalactivators
M
em
brane
depolarization
(V
½
=
-20
m
V
to
+
60
m
V
dependent
upon
conditions)
in
the
presence
ofelevated
[C
a 2+]i ,heat
(Q
10
=
8.5
@
+25
m
V
betw
een
15
and
25°C
)
m
em
brane
depolarization
(V
½
=
0
to
+
120
m
V
dependent
upon
conditions),
heat
(Q
10
=
10.3
@
-75
m
V
betw
een
15
and
25°C
)
–
Endogenous
activators
intracellular
C
a 2+
(pEC
50
3.9–6.3)
[-100m
V
–
100m
V][289,293,294,398]
intracellular
C
a 2+
(pEC
50
4.5–6.2)
[-80m
V
–
80m
V][155,241,418]–
M
ouse
extracellular
H
+
(µ
M
range),intracellular
M
g
2+
Activators
BTP2
(pEC
50
8.1)
[-80m
V][398],
decavanadate
(pEC
50
5.7)
[-100m
V][293]
–
2-APB
(Potentiation)
(pEC
50
3.4–3.7)
[-120m
V
–
100m
V][230]
G
ating
inhibitors
flufenam
ic
acid
(pIC
50
5.6)
[100m
V][418]–
M
ouse,clotrim
azole
C
oncentration
range:
1×
10 −
6M
-1×
10 −
5M
[100m
V][297]
–
–
Endogenous
channelblockers
–
–
M
g
2+
(inw
ard
current
m
ediated
by
m
onovalent
cations
is
blocked)
(pIC
50
5.5–6),
C
a 2+
(inw
ard
current
m
ediated
by
m
onovalent
cations
is
blocked)
(pIC
50
5.3–5.3)
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(continued)
N
om
enclature
TRPM
4
TRPM
5
TRPM
6
C
hannelblockers
9-phenanthrol(pIC
50
4.6–4.8)
[122],
sperm
ine
(pIC
50
4.2)
[100m
V][295],
adenosine
(pIC
50
3.2)
flufenam
ic
acid
(pIC
50
4.6),
intracellular
sperm
ine
(pIC
50
4.4),
Extracellular
H
+
(pIC
50
3.2)
ruthenium
red
(pIC
50
7)
[voltage
dependent-120m
V]
FunctionalC
haracteristics
γ
=
23
pS
(w
ithin
the
range
60
to
+60
m
V);
perm
eable
to
m
onovalent
cations;
im
perm
eable
to
C
a 2+;strong
outw
ard
rectification;slow
activation
at
positive
potentials,rapid
deactivation
at
negative
potentials,deactivation
blocked
by
decavanadate
γ
=
15-25
pS;conducts
m
onovalent
cations
selectively
(P
C
a /P
N
a
=
0.05);
strong
outw
ard
rectification;slow
activation
at
positive
potentials,rapid
inactivation
at
negative
potentials;
activated
and
subsequently
desensitized
by
[C
a 2+]I
γ=
40–87
pS;perm
eable
to
m
ono-and
di-valent
cations
w
ith
a
preference
for
divalents
(M
g
2+
>
C
a 2+;P
C
a /P
N
a
=
6.9),conductance
sequence
Zn
2+
>
Ba 2+
>
M
g
2+=
C
a 2+
=
M
n
2+
>
Sr 2+
>
C
d
2+>
N
i 2+;strong
outw
ard
rectification
abolished
by
rem
ovalofextracellular
divalents,inhibited
by
intracellular
M
g
2+
(IC
50
=
0.5
m
M
)
and
ATP
C
om
m
ents
–
TRPM
5
is
not
blocked
by
ATP
–
N
om
enclature
TRPM
7
TRPM
8
H
G
N
C
,U
niProt
TRPM
7,Q
96Q
T4
TRPM
8,Q
7Z2W
7
EC
num
ber
2.7.11.1
–
Physicalactivators
–
depolarization
(V
½ ˜+50
m
V
at
15°C
),cooling
(<
22-26°C
)
Endogenous
activators
intracellular
ATP,Extracellular
H
+,cyclic
AM
P
(elevated
cAM
P
levels)
–
Activators
2-APB
C
oncentration
range:>1×
10 −
3M
[279]–
M
ouse
icilin
(pEC
50
6.7–6.9)
[physiologicalvoltage][9,28]–
M
ouse,
(-)-m
enthol(inhibited
by
intracellular
C
a 2+)
(pEC
50
4.6)
[-120m
V
–
160m
V][423]
Selective
activators
–
W
S-12
(pEC
50
4.9)
[physiologicalvoltage][249,369]–
Rat
C
hannelblockers
sperm
ine
(Reversible,voltage
dependent
inhibition
in
RBL2H
3
rats)
(pK
i 5.6)
[-110m
V
–
80m
V][206]–
Rat,2-APB
(Reversible
inhibition)
(pIC
50
3.8)
[-100m
V
–
100m
V][230]–
M
ouse,carvacrol(Reversible
inhibition)
(pIC
50
3.5)
[-100m
V
–
100m
V][310]–
M
ouse,M
g
2+
(Reversible
inhibition)
(pIC
50
2.5)
[80m
V][279]–
M
ouse,La 3+
C
oncentration
range:2×
10 −
3M
[-100m
V
–
100m
V][356]–
M
ouse
BC
TC
(pIC
50
6.1)
[physiologicalvoltage][28]–
M
ouse,2-APB
(pIC
50
4.9–5.1)
[100m
V
–
-100m
V][157,284]–
M
ouse,capsazepine
(pIC
50
4.7)
[physiologicalvoltage][28]–
M
ouse
FunctionalC
haracteristics
γ
=
40-105
pS
at
negative
and
positive
potentials
respectively;conducts
m
ono-and
di-valent
cations
w
ith
a
preference
for
m
onovalents
(P
C
a /P
N
a
=
0.34);conductance
sequence
N
i 2+
>
Zn
2+
>
Ba 2+
=
M
g
2+
>
C
a 2+
=
M
n
2+
>
Sr 2+
>
C
d
2+;outw
ard
rectification,decreased
by
rem
ovalofextracellular
divalent
cations;inhibited
by
intracellular
M
g
2+,Ba 2+,Sr 2+,Zn
2+,M
n
2+
and
M
g.ATP
(disputed);
activated
by
and
intracellular
alkalinization;sensitive
to
osm
otic
gradients
γ
=
40-83
pS
at
positive
potentials;conducts
m
ono-and
di-valent
cations
non-selectively
(P
C
a /P
N
a
=
1.0–3.3);pronounced
outw
ard
rectification;dem
onstrates
densensitization
to
chem
icalagonists
and
adaptation
to
a
cold
stim
ulus
in
the
presence
ofC
a 2+;m
odulated
by
lysophospholipids
and
PU
FAs
C
om
m
ents
2-APB
acts
as
a
channelblocker
in
the
µ
M
range.
cannabidioland
#
9-tetrahydrocannabinolare
exam
ples
of
cannabinoid
activators.TRPM
8
is
insensitive
to
ruthenium
red.icilin
requires
intracellular
C
a 2+
for
fullagonist
activity.
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T
R
P
M
L
(m
u
co
lip
in
)
fam
ily
Th
e
TR
PM
L
fam
ily
[75,
336,
339,
463,
476]
con
sists
of
th
ree
m
am
m
alian
m
em
bers
(TR
PM
L1-3).
TR
PM
L
ch
an
n
els
are
proba-
bly
restricted
to
in
tracellular
vesicles
an
d
m
utation
s
in
th
e
gen
e
(M
C
O
LN
1)
en
codin
g
TR
PM
L1
(m
ucolipin
-1)
are
on
e
cause
of
th
e
n
eurodegen
erative
disorderm
ucolipidosis
type
IV
(M
LIV
)in
m
an
.
TR
PM
L1
isa
cation
selective
ion
ch
an
n
elth
atisim
portan
tforsort-
in
g/tran
sport
of
en
dosom
es
in
th
e
late
en
docytotic
path
w
ay
an
d
specifically
fusion
betw
een
late
en
dosom
e-lysosom
e
h
ybrid
vesi-
cles.TR
PM
L2
an
d
TR
PM
L3
sh
ow
in
creased
ch
an
n
elactivity
in
low
extracellular
sodium
an
d
are
activated
by
sim
ilar
sm
allm
olecules
[125].
TR
PM
L3
is
im
portan
t
for
h
air
cell
m
aturation
,
stereocilia
m
aturation
an
d
in
tracellular
vesicle
tran
sport.
A
n
aturally
occur-
rin
g
gain
of
fun
ction
m
utation
in
TR
PM
L3
(i.e.
A
419P)
results
in
th
e
varitin
t
w
addler
(V
a)
m
ouse
ph
en
otype
(review
ed
by
[292,
339]).
N
om
enclature
TRPM
L1
TRPM
L2
TRPM
L3
H
G
N
C
,U
niProt
M
CO
LN
1,Q
9G
ZU
1
M
CO
LN
2,Q
8IZK6
M
CO
LN
3,Q
8TD
D
5
Activators
TRPM
L1
Va:C
onstitutively
active,current
potentiated
by
extracellular
acidification
(equivalent
to
intralysosom
al
acidification)
TRPM
L2
Va:C
onstitutively
active,current
potentiated
by
extracellular
acidification
(equivalent
to
intralysosom
alacidification)
TRPM
L3
Va:C
onstitutively
active,current
inhibited
by
extracellular
acidification
(equivalent
to
intralysosom
al
acidicification)
W
ild
type
TRPM
L3:Activated
by
N
a +-free
extracellular
(extracytosolic)
solution
and
m
em
brane
depolarization,current
inhibited
by
extracellular
acidification
(equivalent
to
intralysosom
al
acidicification)
C
hannelblockers
G
d
3+
(pIC
50
4.7)
[-80m
V][281]–
M
ouse
FunctionalC
haracteristics
TRPM
L1
Va:γ
=
40
pS
and
76-86
pS
at
very
negative
holding
potentials
w
ith
Fe 2+
and
m
onovalent
cations
as
charge
carriers,
respectively;conducts
N
a +∼=
K
+>
C
s +
and
divalent
cations
(Ba 2+>
M
n2
+>
Fe 2+>
C
a 2+>
M
g
2+>
N
i 2+>
C
o
2+>
C
d
2+>
Zn
2+≫
C
u
2+)
protons;m
onovalent
cation
flux
suppressed
by
divalent
cations
(e.g.C
a 2+,Fe 2+);inw
ardly
rectifying
TRPM
L1
Va:C
onducts
N
a +;m
onovalent
cation
flux
suppressed
by
divalent
cations;inw
ardly
rectifying
TRPM
L3
Va:γ
=
49
pS
at
very
negative
holding
potentials
w
ith
m
onovalent
cations
as
charge
carrier;
conducts
N
a +
>
K
+
>
C
s +
w
ith
m
aintained
current
in
the
presence
ofN
a +,conducts
C
a 2+
and
M
g
2+,but
not
Fe 2+,im
perm
eable
to
protons;inw
ardly
rectifying
W
ild
type
TRPM
L3:γ
=
59
pS
at
negative
holding
potentials
w
ith
m
onovalent
cations
as
charge
carrier;
conducts
N
a +
>
K
+
>
C
s +
and
C
a 2+
(P
C
a /P
K ∼=
350),
slow
ly
inactivates
in
the
continued
presence
ofN
a +
w
ithin
the
extracellular
(extracytosolic)
solution;
outw
ardly
rectifying
T
R
P
P
(p
o
lycystin
)
fam
ily
Th
e
TR
PP
fam
ily
(review
ed
by
[87,89,118,153,451])or
PK
D
2
fam
ily
is
com
prised
ofPK
D
2,PK
D
2L1
an
d
PK
D
2L2,w
h
ich
h
ave
been
ren
am
ed
TR
PP1,TR
PP2
an
d
TR
PP3,respectively
[455].Th
ey
are
clearly
distin
ct
from
th
e
PK
D
1
fam
ily,w
h
ose
fun
ction
is
un
kn
ow
n
.A
lth
ough
stillbein
g
sorted
out,TR
PP
fam
ily
m
em
bers
appear
to
be
6TM
span
n
in
g
n
on
selective
cation
ch
an
n
els.
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N
om
enclature
TRPP1
TRPP2
TRPP3
H
G
N
C
,U
niProt
PKD
2,Q
13563
PKD
2L1,Q
9P0L9
PKD
2L2,Q
9N
ZM
6
Activators
–
C
alm
idazolium
(in
prim
ary
cilia):10
µ
M
–
C
hannelblockers
–
phenam
il(pIC
50
6.9),benzam
il(pIC
50
6),ethylisopropylam
iloride
(pIC
50
5),am
iloride
(pIC
50
3.8),G
d
3+
C
oncentration
range:1×
10 −
4M
[-50m
V][59],La 3+
C
oncentration
range:
1×
10 −
4M
[-50m
V][59],flufenam
ate
–
FunctionalC
haracteristics
The
channelproperties
ofTRPP1
(PKD
2)
have
not
been
determ
ined
C
urrents
have
been
m
easured
directly
from
prim
ary
cilia
and
also
w
hen
expressed
on
plasm
a
m
em
branes.Prim
ary
cilia
appear
to
contain
heterom
eric
TRPP2
+
PKD
1-L1,underlying
a
gently
outw
ardly
rectifying
nonselective
conductance
(P
C
a /P
N
a ˜6:PKD
1-L1
is
a
12
TM
protein
ofunknow
n
topology).Prim
ary
cilia
heterom
eric
channels
have
an
inw
ard
single
channelconductance
of80
pS
and
an
outw
ard
single
channelconductance
of95
pS.
Presum
ed
hom
om
eric
TRPP2
channels
are
gently
outw
ardly
rectifying.Single
channel
conductance
is
120
pS
inw
ard,200
pS
outw
ard
[82].
–
T
R
P
V
(van
illo
id
)
fam
ily
M
em
bers
of
th
e
TR
PV
fam
ily
(review
ed
by
[421])
can
broadly
be
divided
in
to
th
e
n
on
-selective
cation
ch
an
n
els,TR
PV
1-4
an
d
th
e
m
ore
calcium
selective
ch
an
n
els
TR
PV
5
an
d
TR
PV
6.
T
R
P
V
1-V
4
su
b
fam
ily
TR
PV
1
is
in
volved
in
th
e
developm
en
t
of
th
erm
al
h
yperalgesia
follow
in
g
in
flam
m
ation
an
d
m
ay
con
tribute
to
th
e
detection
of
n
oxius
h
eat
(review
ed
by
[330,382,395]).
N
um
erous
splice
vari-
an
ts
of
TR
PV
1
h
ave
been
described,som
e
of
w
h
ich
m
odulate
th
e
activity
ofTR
PV
1,oractin
a
dom
in
an
tn
egative
m
an
n
erw
h
en
co-
expressed
w
ith
TR
PV
1
[366].
Th
e
ph
arm
acology
of
TR
PV
1
ch
an
-
n
elsisdiscussed
in
detailin
[132]an
d
[427].TR
PV
2
isprobably
n
ot
a
th
erm
osen
sor
in
m
an
[309],but
h
as
recen
tly
been
im
plicated
in
in
n
ate
im
m
un
ity
[238].
TR
PV
3
an
d
TR
PV
4
are
both
th
erm
osen
-
sitive.
Th
ere
are
claim
s
th
at
TR
PV
4
is
also
m
ech
an
osen
sitive,but
th
is
h
as
n
otbeen
establish
ed
to
be
w
ith
in
a
ph
ysiologicalran
ge
in
a
n
ative
en
viron
m
en
t
[47,232].
T
R
P
V
5/V
6
su
b
fam
ily
U
n
der
ph
ysiological
con
dition
s,
TR
PV
5
an
d
TR
PV
6
are
calcium
selective
ch
an
n
els
in
volved
in
th
e
absorption
an
d
reabsorption
of
calcium
across
in
testin
alan
d
kidn
ey
tubule
epith
elia
(review
ed
by
[81,104,278,449]).
N
om
enclature
TRPV1
TRPV2
H
G
N
C
,U
niProt
TRPV1,Q
8N
ER1
TRPV2,Q
9Y5S1
O
ther
chem
icalactivators
N
O
-m
ediated
cysteine
S-nitrosylation
–
Physicalactivators
depolarization
(V
½ ˜0
m
V
at
35°C
),noxious
heat
(>
43°C
at
pH
7.4)
noxious
heat
(>
35°C
;rodent,not
hum
an)
[285]
Endogenous
activators
extracellular
H
+
(at
37°C
)
(pEC
50
5.4),12S-H
PETE
(pEC
50
5.1)
[-60m
V][161]–
Rat,15S-H
PETE
(pEC
50
5.1)
[-60m
V][161]–
Rat,LTB
4
(pEC
50
4.9)
[-60m
V][161]–
Rat,5S-H
ETE
–
Activators
resiniferatoxin
(pEC
50
8.4)
[physiologicalvoltage][374],capsaicin
(pEC
50
7.5)
[-100m
V
–
160m
V][423],cam
phor,diphenylboronic
anhydride,phenylacetylrinvanil[12]
2-APB
(pEC
50
5)
[285,340]–
Rat,#
9-tetrahydrocannabinol(pEC
50
4.8)
[340]–
Rat,cannabidiol(pEC
50
4.5)
[340],probenecid
(pEC
50
4.5)
[15]–
Rat,2-APB
(pEC
50
3.8–3.9)
[physiologicalvoltage][157,179]–
M
ouse,
diphenylboronic
anhydride
C
oncentration
range:1×
10 −
4M
[-80m
V][66,
179]–
M
ouse
Selective
activators
olvanil(pEC
50
7.7)
[physiologicalvoltage][374],D
kTx
(pEC
50
6.6)
[physiologicalvoltage][36]–
Rat
–
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N
om
enclature
TRPV1
TRPV2
C
hannelblockers
5’-iodoresiniferatoxin
(pIC
50
8.4),6-iodo-nordihydrocapsaicin
(pIC
50
8),BC
TC
(pIC
50
7.5)
[57],
capsazepine
(pIC
50
7.4)
[-60m
V][265],ruthenium
red
(pIC
50
6.7–7)
ruthenium
red
(pIC
50
6.2),TRIM
C
oncentration
range:5×
10 −
4M
[179]–
M
ouse
Selective
channelblockers
AM
G
517
(pIC
50
9)
[35],AM
G
628
(pIC
50
8.4)
[435]–
Rat,A425619
(pIC
50
8.3)
[100],A778317
(pIC
50
8.3)
[30],SB366791
(pIC
50
8.2)
[134],JYL1421
(pIC
50
8)
[440]–
Rat,JN
J17203212
(pIC
50
7.8)
[physiologicalvoltage][393],SB452533
(pK
B
7.7),SB705498
(pIC
50
7.1)
[133]
–
Labelled
ligands
[ 3H
]A778317
(C
hannelblocker)
(pK
d
8.5)
[30],[ 125I]resiniferatoxin
(C
hannelblocker)
(pIC
50
8.4)
[-50m
V][430]–
Rat,[ 3H
]resiniferatoxin
(Activator)
–
FunctionalC
haracteristics
γ
=
35
pS
at
–
60
m
V;77
pS
at
+
60
m
V,conducts
m
ono
and
di-valent
cations
w
ith
a
selectivity
for
divalents
(P
C
a /P
N
a
=
9.6);voltage-and
tim
e-dependent
outw
ard
rectification;potentiated
by
ethanol;activated/potentiated/upregulated
by
PKC
stim
ulation;extracellular
acidification
facilitates
activation
by
PKC
;desensitisation
inhibited
by
PKA;inhibited
by
C
a 2+/
calm
odulin;
cooling
reduces
vanilloid-evoked
currents;m
ay
be
tonically
active
at
body
tem
perature
C
onducts
m
ono-and
di-valent
cations
(P
C
a /P
N
a
=
0.9–2.9);dual(inw
ard
and
outw
ard)
rectification;current
increases
upon
repetitive
activation
by
heat;
translocates
to
cellsurface
in
response
to
IG
F-1
to
induce
a
constitutively
active
conductance,translocates
to
the
cellsurface
in
response
to
m
em
brane
stretch
N
om
enclature
TRPV3
TRPV4
H
G
N
C
,U
niProt
TRPV3,Q
8N
ET8
TRPV4,Q
9H
BA0
O
ther
chem
icalactivators
N
O
-m
ediated
cysteine
S-nitrosylation
Epoxyeicosatrieonic
acids
and
N
O
-m
ediated
cysteine
S-nitrosylation
Physicalactivators
depolarization
(V
½ ˜+80
m
V,reduced
to
m
ore
negative
values
follow
ing
heat
stim
uli),heat
(23°C
-39°C
,tem
perature
threshold
reduces
w
ith
repeated
heat
challenge)
C
onstitutively
active,heat
(>
24°C
-32°C
),m
echanicalstim
uli
Activators
incensole
acetate
(pEC
50
4.8)
[273]–
M
ouse,2-APB
(pEC
50
4.6)
[-80m
V
–
80m
V][67]–
M
ouse,diphenylboronic
anhydride
(pEC
50
4.1–4.2)
[voltage
dependent-80m
V
–
80m
V][66]
–
M
ouse,(-)-m
enthol(pEC
50
1.7)
[-80m
V
–
80m
V][252]–
M
ouse,cam
phor
C
oncentration
range:1×
10 −
3M
-2×
10 −
3M
[-60m
V][271]–
M
ouse,carvacrolC
oncentration
range:
5×
10 −
4M
[-80m
V
–
80m
V][461]–
M
ouse,eugenolC
oncentration
range:3×
10 −
3M
[-80m
V
–
80m
V][461]–
M
ouse,thym
olC
oncentration
range:5×
10 −
4M
[-80m
V
–
80m
V][461]–
M
ouse
phorbol12-m
yristate
13-acetate
(pEC
50
7.9)
[physiologicalvoltage][459]
Selective
activators
6-tert-butyl-m
-cresol(pEC
50
3.4)
[426]–
M
ouse
G
SK1016790A
(pEC
50
8.7)
[physiologicalvoltage][409],4α
-PD
H
(pEC
50
7.1)
[physiologicalvoltage][198]–
M
ouse,RN
1747
(pEC
50
6.1)
[physiological
voltage][422],bisandrographolide
(pEC
50
6)
[-60m
V][377]–
M
ouse,4α
-PD
D
C
oncentration
range:3×
10 −
7M
[physiologicalvoltage][459]
C
hannelblockers
diphenyltetrahydrofuran
(pIC
50
5–5.2)
[-80m
V
–
80m
V][66]–
M
ouse,ruthenium
red
C
oncentration
range:1×
10 −
6M
[-60m
V][322]–
M
ouse
G
d
3+,La 3+,ruthenium
red
C
oncentration
range:1×
10 −
6M
[physiological
voltage][172],ruthenium
red
C
oncentration
range:2×
10 −
7M
[physiological
voltage][131]–
Rat
Selective
channelblockers
–
H
C
067047
(pIC
50
7.3)
[-40m
V][102],RN
1734
(pIC
50
5.6)
[physiological
voltage][422]
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(continued)
N
om
enclature
TRPV3
TRPV4
FunctionalC
haracteristics
γ
=
197
pS
at
=
+40
to
+80
m
V,48
pS
at
negative
potentials;conducts
m
ono-and
di-valent
cations;outw
ard
rectification;potentiated
by
arachidonic
acid
γ
=˜60
pS
at
–60
m
V,˜90-100
pS
at
+60
m
V;conducts
m
ono-and
di-valent
cations
w
ith
a
preference
for
divalents
(P
C
a /P
N
a
=6–10);dual(inw
ard
and
outw
ard)
rectification;potentiated
by
intracellular
C
a 2+
via
C
a 2+/
calm
odulin;
inhibited
by
elevated
intracellular
C
a 2+via
an
unknow
n
m
echanism
(IC
50
=
0.4
µ
M
)
N
om
enclature
TRPV5
TRPV6
H
G
N
C
,U
niProt
TRPV5,Q
9N
Q
A5
TRPV6,Q
9H
1D
0
O
ther
channelblockers
Pb
2+
=
C
u
2+
=
G
d
3+
>
C
d
2+
>
Zn
2+
>
La 3+
>
C
o
2+
>
Fe 2
–
Activators
constitutively
active
(w
ith
strong
buffering
ofintracellular
C
a 2+)
2-APB
constitutively
active
(w
ith
strong
buffering
ofintracellular
C
a 2+)
C
hannelblockers
ruthenium
red
(pIC
50
6.9),M
g
2+
ruthenium
red
(pIC
50
5)
[-80m
V][152]–
M
ouse,C
d
2+,La 3+,M
g
2+
FunctionalC
haracteristics
γ
=
59–78
pS
for
m
onovalent
ions
at
negative
potentials,conducts
m
ono-and
di-valents
w
ith
high
selectivity
fordivalents
(P
C
a /P
N
a
>
107);voltage-and
tim
e-dependentinw
ard
rectification;inhibited
by
intracellular
C
a 2+
prom
oting
fast
inactivation
and
slow
dow
nregulation;feedback
inhibition
by
C
a 2+
reduced
by
calcium
binding
protein
80-K-H
;inhibited
by
extracellular
and
intracellular
acidosis;upregulated
by
1,25-dihydrovitam
in
D
3
γ
=
58–79
pS
for
m
onovalent
ions
at
negative
potentials,conducts
m
ono-and
di-valents
w
ith
high
selectivity
for
divalents
(P
C
a /P
N
a
>
130);voltage-and
tim
e-dependent
inw
ard
rectification;inhibited
by
intracellular
C
a 2+
prom
oting
fast
and
slow
inactivation;gated
by
voltage-dependent
channelblockade
by
intracellular
M
g
2+;slow
inactivation
due
to
C
a 2+-dependent
calm
odulin
binding;
phosphorylation
by
PKC
inhibits
C
a 2+-calm
odulin
binding
and
slow
inactivation;
upregulated
by
1,25-dihydroxyvitam
in
D
3
C
o
m
m
en
ts:
T
R
PA
(an
k
yrin
)
fam
ily
A
gen
ts
activatin
g
TR
PA
1
in
a
covalen
t
m
an
n
er
are
th
iol
reactive
electroph
iles
th
at
bin
d
to
cystein
e
an
d
lysin
e
residues
w
ith
in
th
e
cytoplasm
ic
dom
ain
ofth
e
ch
an
n
el[149,250].TR
PA
1
is
activated
by
a
w
ide
ran
ge
of
en
dogen
ous
an
d
exogen
ous
com
poun
ds
an
d
on
ly
a
few
represen
tative
exam
ples
are
m
en
tion
ed
in
th
e
table:
an
exh
austive
listin
g
can
be
foun
d
in
[16].
In
addition
,TR
PA
1
is
poten
tly
activated
by
in
tracellular
zin
c
(EC
50
=
8
n
M
)
[10,156].
T
R
P
M
(m
elastatin
)
fam
ily
C
a 2+
activates
all
splice
varian
ts
of
TR
PM
2,
but
oth
er
activa-
tors
listed
are
effective
on
ly
at
th
e
full
len
gth
isoform
[96].
In
h
ibition
of
TR
PM
2
by
clotrim
azole,
m
icon
azole,
econ
azole,
flufen
am
ic
acid
is
largely
irreversible.
TR
PM
4
exists
as
m
ulti-
ple
spice
varian
ts:
data
listed
are
for
TR
PM
4b.
Th
e
sen
sitivity
of
TR
PM
4b
an
d
TR
PM
5
to
activation
by
[C
a 2+]i
dem
on
strates
a
pron
oun
ced
an
d
tim
e-depen
den
t
reduction
follow
in
g
excision
of
in
side-out
m
em
bran
e
patch
es
[418].
Th
e
V
½
for
activation
of
TR
PM
4
an
d
TR
PM
5
dem
on
strates
a
pron
oun
ced
n
egative
sh
ift
w
ith
in
creasin
g
tem
perature.
A
ctivation
of
TR
PM
8
by
depolariza-
tion
is
stron
gly
tem
perature-depen
den
t
via
a
ch
an
n
el-closin
g
rate
th
at
decreases
w
ith
decreasin
g
tem
perature.
Th
e
V
½
is
sh
ifted
in
th
e
h
yperpolarizin
g
direction
both
by
decreasin
g
tem
perature
an
d
by
exogen
ous
agon
ists,such
as
(-)-m
en
th
ol[423]w
h
ereas
an
tago-
n
istsproduce
depolarizin
g
sh
iftsin
V
½
[276].Th
e
V
½
forth
e
n
ative
ch
an
n
elis
farm
ore
positive
th
an
th
atofh
eterologously
expressed
TR
PM
8
[276].Itsh
ould
be
n
oted
th
at(-)-m
en
th
olan
d
structurally
related
com
poun
dscan
elicitrelease
ofC
a 2+
from
th
e
en
doplasm
ic
reticulum
in
depen
den
t
of
activation
of
TR
PM
8
[254].
In
tracellu-
lar
pH
m
odulates
activation
of
TR
PM
8
by
cold
an
d
icilin
,but
n
ot
(-)-m
en
th
ol[9].
T
R
P
M
L
(m
u
co
lip
in
)
fam
ily
D
ata
in
th
e
table
are
for
TR
PM
L
protein
s
m
utated
(i.e
TR
PM
L1
V
a,
TR
PM
L2
V
a
an
d
TR
PM
L3
V
a)atlociequivalen
tto
TR
PM
L3
A
419P
to
allow
plasm
a
m
em
bran
e
expression
w
h
en
expressed
in
H
EK
-293
cells
an
d
subsequen
t
ch
aracterisation
by
patch
-clam
p
recordin
g
[94,123,191,281,462].
D
ata
for
w
ild
type
TR
PM
L3
are
also
tab-
ulated
[191,
192,
281,
462].
It
sh
ould
be
n
oted
th
at
altern
ative
m
eth
odologies,particularly
in
th
e
case
of
TR
PM
L1,h
ave
resulted
in
ch
an
n
els
w
ith
differin
g
bioph
ysicalch
aracteristics
(review
ed
by
[336]).
T
R
P
P
(p
o
lycystin
)
fam
ily
D
ata
in
th
e
table
are
extracted
from
[79,
89]
an
d
[370].
Broadly
sim
ilar
sin
gle
ch
an
n
el
con
ductan
ce,
m
on
o-
an
d
di-valen
t
cation
selectivity
an
d
sen
sitivity
to
blockers
are
observed
for
TR
PP2
co-
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expressed
w
ith
TR
PP1
[88].
C
a 2+,Ba 2+
an
d
Sr 2+
perm
eate
TR
PP3,
but
reduce
in
w
ard
curren
ts
carried
by
N
a +.M
g
2+
is
largely
im
per-
m
ean
t
an
d
exerts
a
voltage
depen
den
t
in
h
ibition
th
at
in
creases
w
ith
h
yperpolarization
.
T
R
P
V
(van
illo
id
)
fam
ily
A
ctivation
of
TR
PV
1
by
depolarisation
is
stron
gly
tem
perature-
depen
den
t
via
a
ch
an
n
elopen
in
g
rate
th
at
in
creases
w
ith
in
creas-
in
g
tem
perature.
Th
e
V
½
is
sh
ifted
in
th
e
h
yperpolarizin
g
di-
rection
both
by
in
creasin
g
tem
perature
an
d
by
exogen
ous
ago-
n
ists
[423].
Th
e
sen
sitivity
of
TR
PV
4
to
h
eat,
but
n
ot
4α
-PD
D
is
lost
upon
patch
excision
.
TR
PV
4
is
activated
by
an
an
dam
ide
an
d
arach
idon
ic
acid
follow
in
g
P450
epoxygen
ase-depen
den
t
m
etabolism
to
5,6-epoxyeicosatrien
oic
acid
(review
ed
by
[296]).
A
ctivation
of
TR
PV
4
by
cellsw
ellin
g,but
n
ot
h
eat,or
ph
orboles-
ters,
is
m
ediated
via
th
e
form
ation
of
epoxyeicosatrieon
ic
acids.
Ph
orbol
esters
bin
d
directly
to
TR
PV
4.
TR
PV
5
preferen
tially
con
-
ducts
C
a 2+
un
der
ph
ysiologicalcon
dition
s,but
in
th
e
absen
ce
of
extracellular
C
a 2+,
con
ducts
m
on
ovalen
t
cation
s.
Sin
gle
ch
an
-
n
elcon
ductan
ces
listed
for
TR
PV
5
an
d
TR
PV
6
w
ere
determ
in
ed
in
divalen
t
cation
-free
extracellular
solution
.
C
a 2+-in
duced
in
acti-
vation
occurs
at
h
yperpolarized
poten
tials
w
h
en
C
a 2+
is
presen
t
extracellularly.
Sin
gle
ch
an
n
el
even
ts
can
n
ot
be
resolved
(proba-
bly
due
to
greatly
reduced
con
ductan
ce)
in
th
e
presen
ce
of
extra-
cellulardivalen
tcation
s.M
easurem
en
ts
ofP
C
a /P
N
a
forTR
PV
5
an
d
TR
PV
6
are
depen
den
t
upon
ion
ic
con
dition
s
due
to
an
om
alous
m
ole
fraction
beh
aviour.Blockade
ofTR
PV
5
an
d
TR
PV
6
by
extra-
cellular
M
g
2+
is
voltage-depen
den
t.In
tracellular
M
g
2+
also
exerts
a
voltage
depen
den
t
block
th
at
is
alleviated
by
h
yperpolarization
an
d
con
tributes
to
th
e
tim
e-depen
den
t
activation
an
d
deactiva-
tion
of
TR
PV
6
m
ediated
m
on
ovalen
t
cation
curren
ts.
TR
PV
5
an
d
TR
PV
6
differ
in
th
eir
kin
etics
ofC
a 2+-depen
den
t
in
activation
an
d
recovery
from
in
activation
.TR
PV
5
an
d
TR
PV
6
fun
ction
as
h
om
o-
an
d
h
etero-tetram
ers.
Fu
rth
er
read
in
g
o
n
T
ran
sien
t
R
ecep
to
r
P
o
ten
tial
ch
an
n
els
A
gh
azadeh
Tabrizi
M
et
al.
(2017)
M
edicin
al
C
h
em
istry,
Ph
arm
acology,
an
d
C
lin
ical
Im
plication
s
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1
R
eceptor
A
n
tagon
ists.
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sien
t
R
eceptor
Poten
tialC
h
an
n
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n
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ID
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X
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C
om
pen
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voltage-gated
ion
ch
an
n
els:
tran
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t
receptor
poten
tial
ch
an
n
els.
Pharm
acol
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[PM
ID
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D
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I
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A
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d
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A
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Tran
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t
R
eceptor
Poten
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h
an
n
els.
A
nnu
Rev
Biophys
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:371-98
[PM
ID
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G
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M
S
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M
odulation
of
th
e
TR
PV
4
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ch
an
n
el
as
a
th
erapeutic
target
for
disease.
Pharm
acolT
her
[PM
ID
:28202366]
G
rayson
TH
et
al.
(2017)
Tran
sien
t
receptor
poten
tialcan
on
icaltype
3
ch
an
n
els:
In
teraction
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an
d
relevan
ce
-A
vascular
focus.Pharm
acolT
her174
:79-96
[PM
ID
:28223224]
K
ash
io
M
etal.
(2017)
Th
e
TR
PM
2
ch
an
n
el:
a
th
erm
o-sen
sitive
m
etabolic
sen
sor.C
hannels
(A
ustin)
0
[PM
ID
:28633002]
W
u
LJ
et
al.
(2010)
In
tern
ation
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology.
LX
X
V
I.
C
ur-
ren
t
progress
in
th
e
m
am
m
alian
TR
P
ion
ch
an
n
el
fam
ily.
Pharm
acol
Rev
62
:
381-404
[PM
ID
:20716668]
Zierler
S
et
al.
(2017)
TR
PM
ch
an
n
els
as
poten
tial
th
erapeutic
targets
again
st
pro-in
flam
m
atory
diseases.
C
ellC
alcium
[PM
ID
:28549569]
Voltage-gated
calcium
channels
V
oltage-gated
ion
ch
an
n
els→
V
oltage-gated
calcium
ch
an
n
els
O
verview
:
C
alcium
(C
a 2+)
ch
an
n
els
are
voltage-gated
ion
ch
an
-
n
els
presen
tin
th
e
m
em
bran
e
ofm
ostexcitable
cells.Th
e
n
om
en
-
clature
for
C
a 2+ch
an
n
els
w
as
proposed
by
[101]
an
d
ap
p
ro
ved
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
C
a
2+
ch
an
n
els
[54].
C
a 2+
ch
an
n
els
form
h
etero-oligom
eric
com
plexes.
Th
e
α
1
sub-
un
it
is
pore-form
in
g
an
d
provides
th
e
bin
din
g
site(s)
for
prac-
tically
all
agon
ists
an
d
an
tagon
ists.
Th
e
10
clon
ed
α
1-subun
its
can
be
grouped
in
to
th
ree
fam
ilies:
(1)
th
e
h
igh
-voltage
acti-
vated
dih
ydropyridin
e-sen
sitive
(L-type,
C
aV
1.x)
ch
an
n
els;
(2)
th
e
h
igh
-voltage
activated
dih
ydropyridin
e-in
sen
sitive
(C
aV
2.x)
ch
an
n
els
an
d
(3)th
e
low
-voltage-activated
(T-type,C
aV
3.x)ch
an
-
n
els.
Each
α
1
subun
it
h
as
four
h
om
ologous
repeats
(I–IV
),
each
repeat
h
avin
g
six
tran
sm
em
bran
e
dom
ain
s
an
d
a
pore-form
in
g
region
betw
een
tran
sm
em
bran
e
dom
ain
s
S5
an
d
S6.
G
atin
g
is
th
ough
t
to
be
associated
w
ith
th
e
m
em
bran
e-span
n
in
g
S4
segm
en
t,
w
h
ich
con
tain
s
h
igh
ly
con
served
positive
ch
arges.
M
an
y
of
th
e
α
1-subun
it
gen
es
give
rise
to
altern
atively
spliced
products.
A
t
least
for
h
igh
-voltage
activated
ch
an
n
els,it
is
likely
th
at
n
ative
ch
an
n
els
com
prise
co-assem
blies
of
α
1,
β
an
d
α
2–δ
subun
its.
Th
e
γ
subun
its
h
ave
n
ot
been
proven
to
associate
w
ith
ch
an
n
els
oth
er
th
an
th
e
α
1s
skeletalm
uscle
C
av1.1
ch
an
n
el.Th
e
α
2–δ1
an
d
α
2–δ2
subun
its
bin
d
gabapen
tin
an
d
pregabalin
.
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
Voltage-gate
calcium
channels
S186
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13884/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Voltage-gated
ion
channels.British
JournalofPharm
acology
(2017)174,S160–S194
N
om
enclature
C
av 1.1
C
av 1.2
C
av 1.3
C
av 1.4
H
G
N
C
,U
niProt
CACN
A1S,Q
13698
CACN
A1C,Q
13936
CACN
A1D
,Q
01668
CACN
A1F,O
60840
Activators
FPL64176
(pEC
50 ∼
7.8),(-)-(S)-BayK8644
(pEC
50 ∼
7.8)
(-)-(S)-BayK8644
(pEC
50 ∼
7.8),FPL64176
C
oncentration
range:1×
10 −
6M
-5×
10 −
6M
[243]–
Rat
FPL64176
(pEC
50 ∼
7.8),(-)-(S)-BayK8644
(pEC
50 ∼
7.8)
(-)-(S)-BayK8644
(pEC
50 ∼
7.8)
G
ating
inhibitors
nifedipine
(pIC
50
6.3)
C
oncentration
range:1×
10 −
7M
-1×
10 −
4M
[voltage
dependent-90m
V][215]–
Rat,
nim
odipine
(pIC
50 ∼
6)
[-70m
V],
nitrendipine
(pIC
50
6)
[-80m
V][25]–
Rat
nifedipine
(pIC
50
7.7)
[-80m
V][329]–
Rat,
nim
odipine
(pIC
50
6.8)
[-80m
V][465]–
Rat,nitrendipine
(pIC
50
6)
[-80m
V][465]–
Rat
nitrendipine
(pIC
50
8.4)
[373],nifedipine
(pIC
50
7.7)
[373],nim
odipine
(pIC
50
5.7–6.6)
[-80m
V
–
-40m
V][357,465]–
Rat
nifedipine
(pIC
50
6)
[-100m
V][267],
nim
odipine
(pIC
50 ∼
6)
[-70m
V],
nitrendipine
(pIC
50 ∼
6)
[-70m
V]
Selective
gating
inhibitors
–
–
–
–
C
hannelblockers
diltiazem
,verapam
il
diltiazem
,verapam
il
verapam
il
diltiazem
(pIC
50
4)
[-80m
V][21]–
M
ouse,verapam
ilC
oncentration
range:1×
10 −
4M
[-80m
V][21]–
M
ouse
Sub/fam
ily-selective
channel
blockers
calciseptine
calciseptine
–
–
FunctionalC
haracteristics
L-type
calcium
current:H
igh
voltage-activated,slow
voltage
dependent
inactivation
L-type
calcium
current:H
igh
voltage-activated,slow
voltage-dependent
inactivation,rapid
calcium
-dependent
inactivation
L-type
calcium
current:Voltage-activated,
slow
voltage-dependent
inactivation,
m
ore
rapid
calcium
-dependent
inactivation
L-type
calcium
current:M
oderate
voltage-activated,slow
voltage-dependent
inactivation
C
om
m
ents
–
–
C
av 1.3
activates
m
ore
negative
potentials
than
C
av 1.2
and
is
incom
pletely
inhibited
by
dihydropyridine
antagonists.
C
av 1.4
is
less
sensitive
to
dihydropyridine
antagonists
than
other
C
av1
channels
N
om
enclature
C
av 2.1
C
av 2.2
C
av 2.3
H
G
N
C
,U
niProt
CACN
A1A,O
00555
CACN
A1B,Q
00975
CACN
A1E,Q
15878
Selective
gating
inhibitors
ω
-agatoxin
IVA
(P
current
com
ponent:Kd
=˜2nM
,Q
com
ponent
Kd=
>
100nM
)
(pIC
50
7–8.7)
[-100m
V
–
-90m
V][38,270]–
Rat,ω
-agatoxin
IVB
(pK
d
8.5)
[-80m
V][4]–
Rat
–
SN
X
482
(pIC
50
7.5–8)
[physiologicalvoltage][286]
C
hannelblockers
–
–
N
i 2+
(pIC
50
4.6)
[-90m
V][448]
Sub/fam
ily-selective
channel
blockers
ω
-conotoxin
M
VIIC
(pIC
50
8.2–9.2)
C
oncentration
range:2×
10 −
6M
-5×
10 −
6M
[physiologicalvoltage]
[229]–
Rat
ω
-conotoxin
G
VIA
(pIC
50
10.4)
[-80m
V][229]–
Rat,
ω
-conotoxin
M
VIIC
(pIC
50
6.1–8.5)
[-80m
V][148,229,
264]–
Rat
–
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N
om
enclature
C
av 2.1
C
av 2.2
C
av 2.3
FunctionalC
haracteristics
P/Q
-type
calcium
current:M
oderate
voltage-activated,
m
oderate
voltage-dependent
inactivation
N
-type
calcium
current:H
igh
voltage-activated,
m
oderate
voltage-dependent
inactivation
R-type
calcium
current:M
oderate
voltage-activated,
fast
voltage-dependent
inactivation
N
om
enclature
C
av 3.1
C
av 3.2
C
av 3.3
H
G
N
C
,U
niProt
CACN
A1G
,O
43497
CACN
A1H
,O
95180
CACN
A1I,Q
9P0X
4
G
ating
inhibitors
kurtoxin
(pIC
50
7.3–7.8)
[-90m
V][63,371]–
Rat
kurtoxin
(pIC
50
7.3–7.6)
[-90m
V][63,371]–
Rat
–
C
hannelblockers
m
ibefradil(pIC
50
6–6.6)
[-110m
V
–
-100m
V][261],
N
i 2+
(pIC
50
3.6–3.8)
[voltage
dependent-90m
V][218]
–
Rat
m
ibefradil(pIC
50
5.9–7.2)
[-110m
V
–
-80m
V][261],
N
i 2+
(pIC
50
4.9–5.2)
[voltage
dependent-90m
V][218]
m
ibefradil(pIC
50
5.8)
[-110m
V][261],N
i 2+
(pIC
50
3.7–4.1)
[voltage
dependent-90m
V][218]–
Rat
FunctionalC
haracteristics
T-type
calcium
current:Low
voltage-activated,fast
voltage-dependent
inactivation
T-type
calcium
current:Low
voltage-activated,fast
voltage-dependent
inactivation
T-type
calcium
current:Low
voltage-activated,
m
oderate
voltage-dependent
inactivation
C
o
m
m
en
ts:In
m
an
y
celltypes,P
an
d
Q
curren
t
com
pon
en
ts
can
n
ot
be
adequately
separated
an
d
m
an
y
research
ers
in
th
e
field
h
ave
adopted
th
e
term
in
ology
‘P/Q
-type’curren
t
w
h
en
referrin
g
to
eith
er
com
pon
en
t.
Both
of
th
ese
ph
ysiologically
defin
ed
curren
t
types
are
con
ducted
by
altern
ative
form
s
of
C
av2.1.
Zicon
otide
(a
syn
th
etic
peptide
equivalen
t
to
ω
-con
otoxin
M
V
IIA
)
h
as
been
approved
for
th
e
treatm
en
t
of
ch
ron
ic
pain
[447].
Fu
rth
er
read
in
g
o
n
V
o
ltag
e-g
ated
calciu
m
ch
an
n
els
C
atterallW
A
etal.(2015)
StructuralBasis
for
Ph
arm
acology
of
V
oltage-G
ated
Sodium
an
d
C
alcium
C
h
an
n
els.
M
olPharm
acol88
:141-50
[PM
ID
:25848093]
C
atterall
W
A
et
al.
(2005)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
X
LV
III.
N
om
en
clature
an
d
structure-fun
ction
relation
sh
ips
of
voltage-gated
calcium
ch
an
n
els.
Pharm
acolRev
57
:
411-25
[PM
ID
:16382099]
C
atterall
W
A
et
al.
(2015)
D
eciph
erin
g
voltage-gated
N
a(+)
an
d
C
a(2+)
ch
an
n
els
by
studyin
g
prokaryotic
an
cestors.Trends
Biochem
Sci40
:526-34
[PM
ID
:26254514]
D
olph
in
A
C
.(2016)
V
oltage-gated
calcium
ch
an
n
els
an
d
th
eir
auxiliary
subun
its:
ph
ysiology
an
d
path
oph
ysiology
an
d
ph
arm
acology.
JPhysiol594
:5369-90
[PM
ID
:27273705]
H
uan
g
Jetal.(2017)R
egulation
ofvoltage
gated
calcium
ch
an
n
els
by
G
PC
R
s
an
d
post-tran
slation
al
m
odification
.
C
urr
O
pin
Pharm
acol32
:1-8
[PM
ID
:27768908]
O
rtn
er
N
J
et
al.
(2016)
L-type
calcium
ch
an
n
els
as
drug
targets
in
C
N
S
disorders.
C
hannels
(A
ustin)
10
:7-13
[PM
ID
:26039257]
R
ougier
JS
etal.(2016)C
ardiac
voltage-gated
calcium
ch
an
n
elm
acrom
olecular
com
plexes.Biochim
Biophys
A
cta
1863
:1806-12
[PM
ID
:26707467]
Zam
pon
iG
W
.(2016)Targetin
g
voltage-gated
calcium
ch
an
n
els
in
n
eurologicalan
d
psych
iatric
dis-
eases.N
atRev
D
rug
D
iscov
15
:19-34
[PM
ID
:26542451]
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Voltage-gated
proton
channel
V
oltage-gated
ion
ch
an
n
els→
V
oltage-gated
proton
ch
an
n
el
O
verview
:
Th
e
voltage-gated
proton
ch
an
n
el
(provision
ally
de-
n
oted
H
v 1)
is
a
putative
4TM
proton
-selective
ch
an
n
el
gated
by
m
em
bran
e
depolarization
an
d
w
h
ich
issen
sitive
to
th
e
tran
sm
em
-
bran
e
pH
gradien
t
[49,
84,
85,
346,
362].
Th
e
structure
of
H
v 1
is
h
om
ologous
to
th
e
voltage
sen
sin
g
dom
ain
(V
SD
)
of
th
e
su-
perfam
ily
of
voltage-gated
ion
ch
an
n
els
(i.e.
segm
en
ts
S1
to
S4)
an
d
con
tain
s
n
o
discern
able
pore
region
[346,
362].
Proton
flux
th
rough
H
v 1
is
in
stead
m
ost
likely
m
ediated
by
a
w
ater
w
ire
com
-
pleted
in
a
crevice
ofth
e
protein
w
h
en
th
e
voltage-sen
sin
g
S4
h
elix
m
oves
in
respon
se
to
a
ch
an
ge
in
tran
sm
em
bran
e
poten
tial[345,
453].
H
v 1
expresses
largely
as
a
dim
er
m
ediated
by
in
tracellular
C
-term
in
alcoiled-coilin
teraction
s
[231]butin
dividualprom
oters
n
on
eth
eless
support
gated
H
+
flux
via
separate
con
duction
path
-
w
ays
[203,221,327,412].W
ith
in
dim
eric
structures,th
e
tw
o
pro-
tom
ers
do
n
ot
fun
ction
in
depen
den
tly,
but
display
co-operative
in
teraction
s
durin
g
gatin
g
resultin
g
in
in
creased
voltage
sen
sitiv-
ity,but
slow
er
activation
,of
th
e
dim
eric,versus
m
on
om
eric,com
-
plexes
[121,413].
N
om
enclature
H
v 1
H
G
N
C
,U
niProt
H
VCN
1,Q
96D
96
C
hannelblockers
Zn
2+
(pIC
50 ∼
5.7–6.3),C
d
2+
(pIC
50 ∼
5)
FunctionalC
haracteristics
Activated
by
m
em
brane
depolarization
m
ediating
m
acroscopic
currents
w
ith
tim
e-,voltage-and
pH
-dependence;outw
ardly
rectifying;voltage
dependent
kinetics
w
ith
relatively
slow
current
activation
sensitive
to
extracellular
pH
and
tem
perature,relatively
fast
deactivation;voltage
threshold
for
current
activation
determ
ined
by
pH
gradient
(#
pH
=
pH
o
-pH
i )
across
the
m
em
brane
C
o
m
m
en
ts:
Th
e
voltage
th
resh
old
(V
th
r )
for
activation
of
H
v1
is
n
ot
fixed
but
is
set
by
th
e
pH
gradien
t
across
th
e
m
em
bran
e
such
th
at
V
th
r
is
positive
to
th
e
N
ern
st
poten
tial
for
H
+,
w
h
ich
en
suresth
aton
ly
outw
ardly
directed
flux
ofH
+
occursun
derph
ys-
iological
con
dition
s
[49,84,85].
Ph
osph
orylation
of
H
v 1
w
ith
in
th
e
N
-term
in
aldom
ain
by
PK
C
en
h
an
ces
th
e
gatin
g
of
th
e
ch
an
-
n
el
[274].
Tabulated
IC
50
values
for
Zn
2+
an
d
C
d
2+
are
for
h
et-
erologously
expressed
h
um
an
an
d
m
ouse
H
v 1
[346,
362].
Zn
2+
is
n
ot
a
con
ven
tion
al
pore
blocker,
but
is
coordin
ated
by
tw
o,
or
m
ore,
extern
al
proton
ation
sites
in
volvin
g
h
istam
in
e
residues
[346].
Zn
2+
bin
din
g
m
ay
occur
at
th
e
dim
er
in
terface
betw
een
pairs
of
h
istam
in
e
residues
from
both
m
on
om
ers
w
h
ere
it
m
ay
in
terfere
w
ith
ch
an
n
el
open
in
g
[275].
M
ouse
kn
ockout
stud-
ies
dem
on
strate
th
at
H
v 1
participates
in
ch
arge
com
pen
sation
in
gran
ulocytes
durin
g
th
e
respiratory
burst
of
N
A
D
PH
oxidase-
depen
den
t
reactive
oxygen
species
production
th
at
assists
in
th
e
clearan
ce
of
bacterial
path
ogen
s
[347].
A
ddition
al
ph
ysiological
fun
ction
s
of
H
v 1
are
review
ed
by
[49].
Fu
rth
er
read
in
g
o
n
V
o
ltag
e-g
ated
p
ro
to
n
ch
an
n
el
C
astillo
K
et
al.
(2015)
V
oltage-gated
proton
(H
(v)1)
ch
an
n
els,a
sin
gular
voltage
sen
sin
g
dom
ain
.
FEBS
Lett589
:3471-8
[PM
ID
:26296320]
D
eC
oursey
TE.(2015)
Th
e
V
oltage-G
ated
Proton
C
h
an
n
el:
A
R
iddle,W
rapped
in
a
M
ystery,in
side
an
En
igm
a.
Biochem
istry
54
:3250-68
[PM
ID
:25964989]
D
eC
oursey
TE.
(2013)
V
oltage-gated
proton
ch
an
n
els:
m
olecular
biology,
ph
ysiology,
an
d
path
o-
ph
ysiology
of
th
e
H
(V
)
fam
ily.
PhysiolRev
93
:599-652
[PM
ID
:23589829]
Fern
an
dez
A
etal.(2016)
Ph
arm
acologicalM
odulation
of
Proton
C
h
an
n
elH
v1
in
C
an
cer
Th
erapy:
Future
Perspectives.
M
olPharm
acol90
:385-402
[PM
ID
:27260771]
O
kam
ura
Y
et
al.
(2015)
G
atin
g
m
ech
an
ism
s
of
voltage-gated
proton
ch
an
n
els.
A
nnu
Rev
Biochem
84
:685-709
[PM
ID
:26034892]
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Voltage-gated
sodium
channels
V
oltage-gated
ion
ch
an
n
els→
V
oltage-gated
sodium
ch
an
n
els
O
verview
:
Sodium
ch
an
n
els
are
voltage-gated
sodium
-selective
ion
ch
an
n
els
presen
t
in
th
e
m
em
bran
e
of
m
ost
excitable
cells.
Sodium
ch
an
n
els
com
prise
ofon
e
pore-form
in
g
α
subun
it,w
h
ich
m
ay
be
associated
w
ith
eith
er
on
e
or
tw
o
β
subun
its
[169].
α
-
Subun
its
con
sist
of
four
h
om
ologous
dom
ain
s
(I–IV
),
each
con
-
tain
in
g
six
tran
sm
em
bran
e
segm
en
ts
(S1–S6)
an
d
a
pore-form
in
g
loop.Th
e
positively
ch
arged
fourth
tran
sm
em
bran
e
segm
en
t
(S4)
acts
as
a
voltage
sen
sor
an
d
is
in
volved
in
ch
an
n
el
gatin
g.
Th
e
crystal
structure
of
th
e
bacterial
N
avA
b
ch
an
n
el
h
as
revealed
a
n
um
berofn
ovelstructuralfeatures
com
pared
to
earlierpotassium
ch
an
n
el
structures
in
cludin
g
a
sh
ort
selectivity
filter
w
ith
ion
se-
lectivity
determ
in
ed
by
in
teraction
s
w
ith
glutam
ate
side
ch
ain
s
[316].
In
terestin
gly,
th
e
pore
region
is
pen
etrated
by
fatty
acyl
ch
ain
sth
atexten
d
in
to
th
e
cen
tralcavity
w
h
ich
m
ay
allow
th
e
en
-
try
ofsm
all,h
ydroph
obic
pore-blockin
g
drugs
[316].A
uxiliary
β1,
β2,β3
an
d
β4
subun
its
con
sist
of
a
large
extracellular
N
-term
in
al
dom
ain
,a
sin
gle
tran
sm
em
bran
e
segm
en
t
an
d
a
sh
orter
cytoplas-
m
ic
dom
ain
.
T
h
e
n
o
m
en
clatu
re
fo
r
so
d
iu
m
ch
an
n
els
w
as
p
ro
p
o
sed
b
y
G
o
ld
in
et
a
l.,
(2000)
[119]
an
d
ap
p
ro
ved
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
so
d
iu
m
ch
an
n
els
(C
atter-
all
et
a
l.,2005,[52]).
N
om
enclature
N
av 1.1
N
av 1.2
N
av 1.3
N
av 1.4
H
G
N
C
,U
niProt
SCN
1A,P35498
SCN
2A,Q
99250
SCN
3A,Q
9N
Y46
SCN
4A,P35499
Sub/fam
ily-selective
activators
batrachotoxin,veratridine
batrachotoxin
(pK
d
9.1)
[physiologicalvoltage]
[237]–
Rat,veratridine
(pK
d
5.2)
[physiological
voltage][53]–
Rat
batrachotoxin,
veratridine
batrachotoxin
C
oncentration
range:5×
10 −
6M
[-100m
V]
[438]–
Rat,veratridine
C
oncentration
range:2×
10 −
4M
[-100m
V][438]–
Rat
C
hannelblockers
tetrodotoxin
(pK
d
8)
[-100m
V]
[378]–
Rat
–
–
–
Sub/fam
ily-selective
channel
blockers
H
m
1a
[306]–
Rat,saxitoxin
saxitoxin
(pIC
50
8.8)
[-120m
V][40]–
Rat,
tetrodotoxin
(pIC
50
8)
[-120m
V][40]–
Rat,
lacosam
ide
(pIC
50
4.5)
[-80m
V][1]–
Rat
tetrodotoxin
(pIC
50
8.4)
[60],saxitoxin
saxitoxin
(pIC
50
8.4)
[-100m
V][324]–
Rat,tetrodotoxin
(pIC
50
7.6)
[-120m
V][56],µ
-conotoxin
G
IIIA
(pIC
50
5.9)
[-100m
V][56]
FunctionalC
haracteristics
Activation
V
0.5
=
-20
m
V.Fast
inactivation
(τ
=
0.7
m
s
for
peak
sodium
current).
Activation
V
0.5
=
-24
m
V.Fast
inactivation
(τ
=
0.8
m
s
for
peak
sodium
current).
Activation
V
0.5
=
-24
m
V.Fast
inactivation
(0.8
m
s)
Activation
V
0.5
=
-30
m
V.Fast
inactivation
(0.6
m
s)
N
om
enclature
N
av 1.5
N
av 1.6
N
av 1.7
N
av 1.8
N
av 1.9
H
G
N
C
,U
niProt
SCN
5A,Q
14524
SCN
8A,Q
9U
Q
D
0
SCN
9A,Q
15858
SCN
10A,Q
9Y5Y9
SCN
11A,Q
9U
I33
Sub/fam
ily-selective
activators
batrachotoxin
(pK
d
7.6)
[physiologicalvoltage]
[368]–
Rat,veratridine
(pEC
50
6.3)
[-30m
V]
[433]–
Rat
batrachotoxin,veratridine
batrachotoxin,veratridine
–
–
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N
om
enclature
N
av 1.5
N
av 1.6
N
av 1.7
N
av 1.8
N
av 1.9
Sub/fam
ily-selective
channelblockers
tetrodotoxin
(pK
d
5.8)
[-80m
V][74,477]–
Rat
tetrodotoxin
(pIC
50
9)
[-130m
V][91]–
Rat,
saxitoxin
tetrodotoxin
(pIC
50
7.6)
[-100m
V]
[199],saxitoxin
(pIC
50
6.2)
[431]
tetrodotoxin
(pIC
50
4.2)
[-60m
V][5]–
Rat
tetrodotoxin
(pIC
50
4.4)
[-120m
V][76]–
Rat
Selective
channelblockers
–
–
–
PF-01247324
(pIC
50
6.7)
[voltage
dependent][317]
–
FunctionalC
haracteristics
Activation
V
0.5
=
-26
m
V.Fast
inactivation
(τ
=
1
m
s
for
peak
sodium
current).
Activation
V
0.5
=
-29
m
V.
Fast
inactivation
(1
m
s)
Activation
V
0.5
=
-27
m
V.Fast
inactivation
(0.5
m
s)
Activation
V
0.5
=
-16
m
V.
Inactivation
(6
m
s)
Activation
V
0.5
=
-32
m
V.
Slow
inactivation
(16
m
s)
C
o
m
m
en
ts:
Sodium
ch
an
n
els
are
also
blocked
by
local
an
aes-
th
etic
agen
ts,an
tiarryth
m
ic
drugs
an
d
an
tiepileptic
drugs.In
gen
-
eral,th
ese
drugs
are
n
oth
igh
ly
selective
am
on
g
ch
an
n
elsubtypes.
Th
ere
are
tw
o
clear
fun
ction
alfin
gerprin
ts
for
distin
guish
in
g
dif-
feren
t
subtypes.
Th
ese
are
sen
sitivity
to
tetrodotoxin
(N
aV
1.5,
N
aV
1.8
an
d
N
aV
1.9
are
m
uch
less
sen
sitive
to
block)
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